<html>

<head>
<meta http-equiv=Content-Type content="text/html; charset=windows-1252">
<meta name=Generator content="Microsoft Word 14 (filtered)">
<style>
<!--
 /* Font Definitions */
 @font-face
	{font-family:Helvetica;
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:Wingdings;
	panose-1:5 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
@font-face
	{font-family:Calibri;
	panose-1:2 15 5 2 2 2 4 3 2 4;}
@font-face
	{font-family:Tahoma;
	panose-1:2 11 6 4 3 5 4 4 2 4;}
@font-face
	{font-family:inherit;
	panose-1:0 0 0 0 0 0 0 0 0 0;}
@font-face
	{font-family:"\@Arial Unicode MS";
	panose-1:2 11 6 4 2 2 2 2 2 4;}
 /* Style Definitions */
 p.MsoNormal, li.MsoNormal, div.MsoNormal
	{margin-top:0in;
	margin-right:0in;
	margin-bottom:10.0pt;
	margin-left:0in;
	line-height:115%;
	font-size:11.0pt;
	font-family:"Calibri","sans-serif";}
h1
	{mso-style-link:"Heading 1 Char";
	margin-right:0in;
	margin-left:0in;
	font-size:24.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
h2
	{mso-style-link:"Heading 2 Char";
	margin-right:0in;
	margin-left:0in;
	font-size:18.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
h3
	{mso-style-link:"Heading 3 Char";
	margin-right:0in;
	margin-left:0in;
	font-size:13.5pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
a:link, span.MsoHyperlink
	{color:blue;
	text-decoration:underline;}
a:visited, span.MsoHyperlinkFollowed
	{color:purple;
	text-decoration:underline;}
p
	{margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.MsoAcetate, li.MsoAcetate, div.MsoAcetate
	{mso-style-link:"Balloon Text Char";
	margin:0in;
	margin-bottom:.0001pt;
	font-size:8.0pt;
	font-family:"Tahoma","sans-serif";}
span.Heading1Char
	{mso-style-name:"Heading 1 Char";
	mso-style-link:"Heading 1";
	font-family:"Times New Roman","serif";
	font-weight:bold;}
span.Heading2Char
	{mso-style-name:"Heading 2 Char";
	mso-style-link:"Heading 2";
	font-family:"Times New Roman","serif";
	font-weight:bold;}
span.Heading3Char
	{mso-style-name:"Heading 3 Char";
	mso-style-link:"Heading 3";
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.ui-button, li.ui-button, div.ui-button
	{mso-style-name:ui-button;
	margin-right:1.2pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-spinner, li.ui-spinner, div.ui-spinner
	{mso-style-name:ui-spinner;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-spinner-input, li.ui-spinner-input, div.ui-spinner-input
	{mso-style-name:ui-spinner-input;
	margin-top:2.4pt;
	margin-right:16.5pt;
	margin-bottom:2.4pt;
	margin-left:4.8pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-helper-hidden-accessible, li.ui-helper-hidden-accessible, div.ui-helper-hidden-accessible
	{mso-style-name:ui-helper-hidden-accessible;
	margin-top:0in;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-buttonset, li.ui-buttonset, div.ui-buttonset
	{mso-style-name:ui-buttonset;
	margin-right:5.25pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker, li.ui-datepicker, div.ui-datepicker
	{mso-style-name:ui-datepicker;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-datepicker-row-break, li.ui-datepicker-row-break, div.ui-datepicker-row-break
	{mso-style-name:ui-datepicker-row-break;
	margin-right:0in;
	margin-left:0in;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-rtl, li.ui-datepicker-rtl, div.ui-datepicker-rtl
	{mso-style-name:ui-datepicker-rtl;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	direction:rtl;
	unicode-bidi:embed;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu, li.ui-menu, div.ui-menu
	{mso-style-name:ui-menu;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar, li.ui-progressbar, div.ui-progressbar
	{mso-style-name:ui-progressbar;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-handle, li.ui-resizable-handle, div.ui-resizable-handle
	{mso-style-name:ui-resizable-handle;
	margin-right:0in;
	margin-left:0in;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-n, li.ui-resizable-n, div.ui-resizable-n
	{mso-style-name:ui-resizable-n;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-s, li.ui-resizable-s, div.ui-resizable-s
	{mso-style-name:ui-resizable-s;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-e, li.ui-resizable-e, div.ui-resizable-e
	{mso-style-name:ui-resizable-e;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-w, li.ui-resizable-w, div.ui-resizable-w
	{mso-style-name:ui-resizable-w;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-se, li.ui-resizable-se, div.ui-resizable-se
	{mso-style-name:ui-resizable-se;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-sw, li.ui-resizable-sw, div.ui-resizable-sw
	{mso-style-name:ui-resizable-sw;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-nw, li.ui-resizable-nw, div.ui-resizable-nw
	{mso-style-name:ui-resizable-nw;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-ne, li.ui-resizable-ne, div.ui-resizable-ne
	{mso-style-name:ui-resizable-ne;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectable-helper, li.ui-selectable-helper, div.ui-selectable-helper
	{mso-style-name:ui-selectable-helper;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectmenu-menu, li.ui-selectmenu-menu, div.ui-selectmenu-menu
	{mso-style-name:ui-selectmenu-menu;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-selectmenu-open, li.ui-selectmenu-open, div.ui-selectmenu-open
	{mso-style-name:ui-selectmenu-open;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectmenu-button, li.ui-selectmenu-button, div.ui-selectmenu-button
	{mso-style-name:ui-selectmenu-button;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider, li.ui-slider, div.ui-slider
	{mso-style-name:ui-slider;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-horizontal, li.ui-slider-horizontal, div.ui-slider-horizontal
	{mso-style-name:ui-slider-horizontal;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-vertical, li.ui-slider-vertical, div.ui-slider-vertical
	{mso-style-name:ui-slider-vertical;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-spinner-button, li.ui-spinner-button, div.ui-spinner-button
	{mso-style-name:ui-spinner-button;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	font-size:6.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tooltip, li.ui-tooltip, div.ui-tooltip
	{mso-style-name:ui-tooltip;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-default, li.ui-state-default, div.ui-state-default
	{mso-style-name:ui-state-default;
	margin-right:0in;
	margin-left:0in;
	background:#E6E6E6;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#555555;}
p.ui-state-focus, li.ui-state-focus, div.ui-state-focus
	{mso-style-name:ui-state-focus;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-hover, li.ui-state-hover, div.ui-state-hover
	{mso-style-name:ui-state-hover;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-active, li.ui-state-active, div.ui-state-active
	{mso-style-name:ui-state-active;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-highlight, li.ui-state-highlight, div.ui-state-highlight
	{mso-style-name:ui-state-highlight;
	margin-right:0in;
	margin-left:0in;
	background:#FBF9EE;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#363636;}
p.ui-state-error, li.ui-state-error, div.ui-state-error
	{mso-style-name:ui-state-error;
	margin-right:0in;
	margin-left:0in;
	background:#FEF1EC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-state-error-text, li.ui-state-error-text, div.ui-state-error-text
	{mso-style-name:ui-state-error-text;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-priority-primary, li.ui-priority-primary, div.ui-priority-primary
	{mso-style-name:ui-priority-primary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.ui-priority-secondary, li.ui-priority-secondary, div.ui-priority-secondary
	{mso-style-name:ui-priority-secondary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-disabled, li.ui-state-disabled, div.ui-state-disabled
	{mso-style-name:ui-state-disabled;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-helper-hidden, li.ui-helper-hidden, div.ui-helper-hidden
	{mso-style-name:ui-helper-hidden;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-helper-reset, li.ui-helper-reset, div.ui-helper-reset
	{mso-style-name:ui-helper-reset;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-helper-zfix, li.ui-helper-zfix, div.ui-helper-zfix
	{mso-style-name:ui-helper-zfix;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-widget-overlay, li.ui-widget-overlay, div.ui-widget-overlay
	{mso-style-name:ui-widget-overlay;
	margin-right:0in;
	margin-left:0in;
	background:#AAAAAA;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-helper-clearfix, li.ui-helper-clearfix, div.ui-helper-clearfix
	{mso-style-name:ui-helper-clearfix;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon, li.ui-icon, div.ui-icon
	{mso-style-name:ui-icon;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-widget-content, li.ui-widget-content, div.ui-widget-content
	{mso-style-name:ui-widget-content;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#222222;}
p.ui-widget-header, li.ui-widget-header, div.ui-widget-header
	{mso-style-name:ui-widget-header;
	margin-right:0in;
	margin-left:0in;
	background:#CCCCCC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#222222;
	font-weight:bold;}
p.ui-widget-shadow, li.ui-widget-shadow, div.ui-widget-shadow
	{mso-style-name:ui-widget-shadow;
	margin-top:0in;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:-6.0pt;
	margin-bottom:.0001pt;
	background:#AAAAAA;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-widget, li.ui-widget, div.ui-widget
	{mso-style-name:ui-widget;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.ui-tabs, li.ui-tabs, div.ui-tabs
	{mso-style-name:ui-tabs;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog, li.ui-dialog, div.ui-dialog
	{mso-style-name:ui-dialog;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-titlebar, li.ui-dialog-titlebar, div.ui-dialog-titlebar
	{mso-style-name:ui-dialog-titlebar;
	margin-right:0in;
	margin-left:0in;
	background:#3E72A6;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.ui-ncbiautocomplete-actions, li.ui-ncbiautocomplete-actions, div.ui-ncbiautocomplete-actions
	{mso-style-name:ui-ncbiautocomplete-actions;
	margin-top:.75pt;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	background:#CECECE;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiautocomplete-link-pref, li.ui-ncbiautocomplete-link-pref, div.ui-ncbiautocomplete-link-pref
	{mso-style-name:ui-ncbiautocomplete-link-pref;
	margin-right:0in;
	margin-left:0in;
	text-indent:-945.65pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibutton, li.ui-ncbibutton, div.ui-ncbibutton
	{mso-style-name:ui-ncbibutton;
	margin-right:1.2pt;
	margin-left:0in;
	text-align:center;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"inherit","serif";}
p.ui-button-icon-only, li.ui-button-icon-only, div.ui-button-icon-only
	{mso-style-name:ui-button-icon-only;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icons-only, li.ui-button-icons-only, div.ui-button-icons-only
	{mso-style-name:ui-button-icons-only;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-outer-div, li.ui-ncbigrid-outer-div, div.ui-ncbigrid-outer-div
	{mso-style-name:ui-ncbigrid-outer-div;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:33.6pt;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-inner-div, li.ui-ncbigrid-inner-div, div.ui-ncbigrid-inner-div
	{mso-style-name:ui-ncbigrid-inner-div;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-filter-toolbar, li.ui-ncbigrid-filter-toolbar, div.ui-ncbigrid-filter-toolbar
	{mso-style-name:ui-ncbigrid-filter-toolbar;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	line-height:20.25pt;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-toolbar, li.ui-ncbigrid-paged-toolbar, div.ui-ncbigrid-paged-toolbar
	{mso-style-name:ui-ncbigrid-paged-toolbar;
	margin-right:0in;
	margin-left:0in;
	line-height:19.4pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-checkbox-toolbar, li.ui-ncbigrid-checkbox-toolbar, div.ui-ncbigrid-checkbox-toolbar
	{mso-style-name:ui-ncbigrid-checkbox-toolbar;
	margin-right:0in;
	margin-left:0in;
	line-height:21.0pt;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-countitems, li.ui-ncbigrid-paged-countitems, div.ui-ncbigrid-paged-countitems
	{mso-style-name:ui-ncbigrid-paged-countitems;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-pagecontrol, li.ui-ncbigrid-paged-pagecontrol, div.ui-ncbigrid-paged-pagecontrol
	{mso-style-name:ui-ncbigrid-paged-pagecontrol;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-toolbar-bottom, li.ui-ncbigrid-paged-toolbar-bottom, div.ui-ncbigrid-paged-toolbar-bottom
	{mso-style-name:ui-ncbigrid-paged-toolbar-bottom;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-select-question, li.ui-ncbigrid-select-question, div.ui-ncbigrid-select-question
	{mso-style-name:ui-ncbigrid-select-question;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	border:none;
	padding:0in;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-ncbigrid-select-question-footer, li.ui-ncbigrid-select-question-footer, div.ui-ncbigrid-select-question-footer
	{mso-style-name:ui-ncbigrid-select-question-footer;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibasicmenu, li.ui-ncbibasicmenu, div.ui-ncbibasicmenu
	{mso-style-name:ui-ncbibasicmenu;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibasicmenuli, li.ui-ncbibasicmenuli, div.ui-ncbibasicmenuli
	{mso-style-name:ui-ncbibasicmenu>li;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.orientationhortli, li.orientationhortli, div.orientationhortli
	{mso-style-name:orientation_hort>li;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbimenu, li.jig-ncbimenu, div.jig-ncbimenu
	{mso-style-name:jig-ncbimenu;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbimenuli, li.jig-ncbimenuli, div.jig-ncbimenuli
	{mso-style-name:jig-ncbimenu>li;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbipopper-wrapper, li.ui-ncbipopper-wrapper, div.ui-ncbipopper-wrapper
	{mso-style-name:ui-ncbipopper-wrapper;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-ncbipopper-basic, li.ui-ncbipopper-basic, div.ui-ncbipopper-basic
	{mso-style-name:ui-ncbipopper-basic;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#303030;}
p.brieflinkpopdesc, li.brieflinkpopdesc, div.brieflinkpopdesc
	{mso-style-name:brieflinkpopdesc;
	margin-top:4.8pt;
	margin-right:0in;
	margin-left:0in;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbitoggler-slave, li.ui-ncbitoggler-slave, div.ui-ncbitoggler-slave
	{mso-style-name:ui-ncbitoggler-slave;
	margin-top:2.4pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.0pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-ncbitoggler-slave-open, li.ui-ncbitoggler-slave-open, div.ui-ncbitoggler-slave-open
	{mso-style-name:ui-ncbitoggler-slave-open;
	margin-top:2.4pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:12.0pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbilinksmenu, li.ui-ncbilinksmenu, div.ui-ncbilinksmenu
	{mso-style-name:ui-ncbilinksmenu;
	margin-right:0in;
	margin-left:0in;
	background:#FCFCFC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#999999;
	font-weight:bold;}
p.ui-ncbilinksmenu-loadingmessage, li.ui-ncbilinksmenu-loadingmessage, div.ui-ncbilinksmenu-loadingmessage
	{mso-style-name:ui-ncbilinksmenu-loadingmessage;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiclearbutton-wrap, li.ui-ncbiclearbutton-wrap, div.ui-ncbiclearbutton-wrap
	{mso-style-name:ui-ncbiclearbutton-wrap;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiexpander, li.ui-ncbiexpander, div.ui-ncbiexpander
	{mso-style-name:ui-ncbiexpander;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiexpander-simple, li.ui-ncbiexpander-simple, div.ui-ncbiexpander-simple
	{mso-style-name:ui-ncbiexpander-simple;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-expander-arrow-bar, li.ui-expander-arrow-bar, div.ui-expander-arrow-bar
	{mso-style-name:ui-expander-arrow-bar;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-expander-controllink, li.ui-expander-controllink, div.ui-expander-controllink
	{mso-style-name:ui-expander-controllink;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbiinpagenav-goto-container, li.jig-ncbiinpagenav-goto-container, div.jig-ncbiinpagenav-goto-container
	{mso-style-name:jig-ncbiinpagenav-goto-container;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbisetswitch, li.ui-ncbisetswitch, div.ui-ncbisetswitch
	{mso-style-name:ui-ncbisetswitch;
	margin-right:0in;
	margin-left:0in;
	background:#F6F6F6;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#444444;}
p.ui-ncbisetswitch-hasstar, li.ui-ncbisetswitch-hasstar, div.ui-ncbisetswitch-hasstar
	{mso-style-name:ui-ncbisetswitch-hasstar;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fg-button-icon-left, li.fg-button-icon-left, div.fg-button-icon-left
	{mso-style-name:fg-button-icon-left;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbihistogram, li.jig-ncbihistogram, div.jig-ncbihistogram
	{mso-style-name:jig-ncbihistogram;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram, li.ui-ncbihistogram, div.ui-ncbihistogram
	{mso-style-name:ui-ncbihistogram;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-display-area, li.ui-ncbihistogram-display-area, div.ui-ncbihistogram-display-area
	{mso-style-name:ui-ncbihistogram-display-area;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-display-areaollih3, li.ui-ncbihistogram-display-areaollih3, div.ui-ncbihistogram-display-areaollih3
	{mso-style-name:ui-ncbihistogram-display-area>ol>li>h3;
	margin:0in;
	margin-bottom:.0001pt;
	text-indent:366.4pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-controls, li.ui-ncbihistogram-controls, div.ui-ncbihistogram-controls
	{mso-style-name:ui-ncbihistogram-controls;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-left, li.ui-ncbihistogram-left, div.ui-ncbihistogram-left
	{mso-style-name:ui-ncbihistogram-left;
	margin-right:0in;
	margin-left:2.25pt;
	text-align:center;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-right, li.ui-ncbihistogram-right, div.ui-ncbihistogram-right
	{mso-style-name:ui-ncbihistogram-right;
	margin-right:2.25pt;
	margin-left:0in;
	text-align:center;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-left-disabled, li.ui-ncbihistogram-left-disabled, div.ui-ncbihistogram-left-disabled
	{mso-style-name:ui-ncbihistogram-left-disabled;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#DDDDDD;}
p.ui-ncbihistogram-right-disabled, li.ui-ncbihistogram-right-disabled, div.ui-ncbihistogram-right-disabled
	{mso-style-name:ui-ncbihistogram-right-disabled;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#DDDDDD;}
p.ui-ncbihistogram-text, li.ui-ncbihistogram-text, div.ui-ncbihistogram-text
	{mso-style-name:ui-ncbihistogram-text;
	margin-top:0in;
	margin-right:12.75pt;
	margin-bottom:0in;
	margin-left:12.75pt;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:21.8pt;
	font-size:10.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbihistogram-tooltip, li.ui-ncbihistogram-tooltip, div.ui-ncbihistogram-tooltip
	{mso-style-name:ui-ncbihistogram-tooltip;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:black;
	display:none;}
p.ncbiactivevalidationmsg, li.ncbiactivevalidationmsg, div.ncbiactivevalidationmsg
	{mso-style-name:ncbiactivevalidation_msg;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ncbiactivevalidationmsgchecking, li.ncbiactivevalidationmsgchecking, div.ncbiactivevalidationmsgchecking
	{mso-style-name:ncbiactivevalidation_msg_checking;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#FF9900;}
p.ncbiactivevalidationmsgvalid, li.ncbiactivevalidationmsgvalid, div.ncbiactivevalidationmsgvalid
	{mso-style-name:ncbiactivevalidation_msg_valid;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:green;}
p.ncbiactivevalidationmsgerror, li.ncbiactivevalidationmsgerror, div.ncbiactivevalidationmsgerror
	{mso-style-name:ncbiactivevalidation_msg_error;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:red;}
p.ncbiactivevalidationmsginfo, li.ncbiactivevalidationmsginfo, div.ncbiactivevalidationmsginfo
	{mso-style-name:ncbiactivevalidation_msg_info;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:blue;}
p.ncbiactivevalidationelerror, li.ncbiactivevalidationelerror, div.ncbiactivevalidationelerror
	{mso-style-name:ncbiactivevalidation_el_error;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.social-buttons, li.social-buttons, div.social-buttons
	{mso-style-name:social-buttons;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.inlinelist, li.inlinelist, div.inlinelist
	{mso-style-name:inline_list;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.inline, li.inline, div.inline
	{mso-style-name:inline;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fig, li.fig, div.fig
	{mso-style-name:fig;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.table, li.table, div.table
	{mso-style-name:table;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.pmc-wm, li.pmc-wm, div.pmc-wm
	{mso-style-name:pmc-wm;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.attic, li.attic, div.attic
	{mso-style-name:attic;
	margin-right:0in;
	margin-left:0in;
	background:#336699;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.basement, li.basement, div.basement
	{mso-style-name:basement;
	margin-right:0in;
	margin-left:0in;
	background:#336699;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-breadcrumbs, li.page-breadcrumbs, div.page-breadcrumbs
	{mso-style-name:page-breadcrumbs;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.first-line-outdent, li.first-line-outdent, div.first-line-outdent
	{mso-style-name:first-line-outdent;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.vatop, li.vatop, div.vatop
	{mso-style-name:va_top;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.vamiddle, li.vamiddle, div.vamiddle
	{mso-style-name:va_middle;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.qtrhythm, li.qtrhythm, div.qtrhythm
	{mso-style-name:qt_rhythm;
	margin-top:4.15pt;
	margin-right:0in;
	margin-bottom:4.15pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.notopmargin, li.notopmargin, div.notopmargin
	{mso-style-name:no_top_margin;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.nobottommargin, li.nobottommargin, div.nobottommargin
	{mso-style-name:no_bottom_margin;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tscanvas, li.tscanvas, div.tscanvas
	{mso-style-name:ts_canvas;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tsbar, li.tsbar, div.tsbar
	{mso-style-name:ts_bar;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#DCF0F4;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fm-reuse, li.fm-reuse, div.fm-reuse
	{mso-style-name:fm-reuse;
	margin-right:0in;
	margin-left:.5in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fm-subtitle, li.fm-subtitle, div.fm-subtitle
	{mso-style-name:fm-subtitle;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	font-size:15.0pt;
	font-family:"Times New Roman","serif";}
p.fm-copyright-license, li.fm-copyright-license, div.fm-copyright-license
	{mso-style-name:fm-copyright-license;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fm-citation-from, li.fm-citation-from, div.fm-citation-from
	{mso-style-name:fm-citation-from;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ft-thumb-box, li.ft-thumb-box, div.ft-thumb-box
	{mso-style-name:ft-thumb-box;
	margin:8.3pt;
	text-align:center;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ft-thumb-current, li.ft-thumb-current, div.ft-thumb-current
	{mso-style-name:ft-thumb-current;
	margin-right:0in;
	margin-left:0in;
	background:#D0DCE8;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tab, li.tab, div.tab
	{mso-style-name:tab;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.arrowtab, li.arrowtab, div.arrowtab
	{mso-style-name:arrowtab;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.blanktab, li.blanktab, div.blanktab
	{mso-style-name:blanktab;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.thistab, li.thistab, div.thistab
	{mso-style-name:thistab;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";
	font-weight:bold;}
p.doi, li.doi, div.doi
	{mso-style-name:doi;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.msg-error, li.msg-error, div.msg-error
	{mso-style-name:msg-error;
	margin-right:0in;
	margin-left:0in;
	background:yellow;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:red;}
p.msg-warning, li.msg-warning, div.msg-warning
	{mso-style-name:msg-warning;
	margin-right:0in;
	margin-left:0in;
	background:yellow;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:brown;}
p.nihms-highlight, li.nihms-highlight, div.nihms-highlight
	{mso-style-name:nihms-highlight;
	margin-top:0in;
	margin-right:2.4pt;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	text-align:center;
	background:yellow;
	font-size:10.5pt;
	font-family:"Times New Roman","serif";
	color:#990000;}
p.head, li.head, div.head
	{mso-style-name:head;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.sub-head, li.sub-head, div.sub-head
	{mso-style-name:sub-head;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.headless, li.headless, div.headless
	{mso-style-name:headless;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.sub-navigation, li.sub-navigation, div.sub-navigation
	{mso-style-name:sub-navigation;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.sec, li.sec, div.sec
	{mso-style-name:sec;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.content-branding, li.content-branding, div.content-branding
	{mso-style-name:content-branding;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.banner-generic-logo-background, li.banner-generic-logo-background, div.banner-generic-logo-background
	{mso-style-name:banner-generic-logo-background;
	margin-right:0in;
	margin-left:0in;
	background:silver;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.banner-journal-name, li.banner-journal-name, div.banner-journal-name
	{mso-style-name:banner-journal-name;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:20.5pt;
	font-family:"Calibri","sans-serif";
	font-variant:small-caps;
	letter-spacing:.3pt;}
p.banner-journal-publisher-over-image, li.banner-journal-publisher-over-image, div.banner-journal-publisher-over-image
	{mso-style-name:banner-journal-publisher-over-image;
	margin-right:7.5pt;
	margin-left:63.0pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.banner-publisher-name, li.banner-publisher-name, div.banner-publisher-name
	{mso-style-name:banner-publisher-name;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:9.5pt;
	font-family:"Calibri","sans-serif";
	color:#AA1111;
	font-weight:bold;}
p.bl-w-jtitle-over, li.bl-w-jtitle-over, div.bl-w-jtitle-over
	{mso-style-name:bl-w-jtitle-over;
	margin-right:0in;
	margin-left:0in;
	font-size:18.0pt;
	font-family:"Times New Roman","serif";
	font-variant:small-caps;}
p.bl-w-jtitle-over-ph, li.bl-w-jtitle-over-ph, div.bl-w-jtitle-over-ph
	{mso-style-name:bl-w-jtitle-over-ph;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.bl-w-jtitle-over-ph-content, li.bl-w-jtitle-over-ph-content, div.bl-w-jtitle-over-ph-content
	{mso-style-name:bl-w-jtitle-over-ph-content;
	margin-top:3.0pt;
	margin-right:6.0pt;
	margin-bottom:3.0pt;
	margin-left:78.75pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.banner-journal-publisher-over-image-elsevierwt, li.banner-journal-publisher-over-image-elsevierwt, div.banner-journal-publisher-over-image-elsevierwt
	{mso-style-name:banner-journal-publisher-over-image-elsevierwt;
	margin-top:0in;
	margin-right:120.0pt;
	margin-bottom:0in;
	margin-left:15.0pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.elsevierwt-sponsored-label, li.elsevierwt-sponsored-label, div.elsevierwt-sponsored-label
	{mso-style-name:elsevierwt-sponsored-label;
	margin-right:0in;
	margin-left:-9.0pt;
	line-height:13.5pt;
	font-size:10.0pt;
	font-family:"Calibri","sans-serif";
	font-variant:small-caps;
	letter-spacing:.9pt;
	font-style:italic;}
p.bl-jtitle-sageopen, li.bl-jtitle-sageopen, div.bl-jtitle-sageopen
	{mso-style-name:bl-jtitle-sageopen;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#0055A5;}
p.bl-jtitle-iospressopenlib, li.bl-jtitle-iospressopenlib, div.bl-jtitle-iospressopenlib
	{mso-style-name:bl-jtitle-iospressopenlib;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-apasd, li.bl-jtitle-apasd, div.bl-jtitle-apasd
	{mso-style-name:bl-jtitle-apasd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#1E73B3;}
p.bl-jtitle-springeropen, li.bl-jtitle-springeropen, div.bl-jtitle-springeropen
	{mso-style-name:bl-jtitle-springeropen;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#F0F0F0;}
p.bl-jtitle-sfesd, li.bl-jtitle-sfesd, div.bl-jtitle-sfesd
	{mso-style-name:bl-jtitle-sfesd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-acssd, li.bl-jtitle-acssd, div.bl-jtitle-acssd
	{mso-style-name:bl-jtitle-acssd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#1E73B3;}
p.bl-jtitle-esesd, li.bl-jtitle-esesd, div.bl-jtitle-esesd
	{mso-style-name:bl-jtitle-esesd;
	margin-right:0in;
	margin-left:0in;
	line-height:33.75pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.bl-jtitle-srfsd, li.bl-jtitle-srfsd, div.bl-jtitle-srfsd
	{mso-style-name:bl-jtitle-srfsd;
	margin-right:0in;
	margin-left:0in;
	line-height:33.75pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.bl-jtitle-tea, li.bl-jtitle-tea, div.bl-jtitle-tea
	{mso-style-name:bl-jtitle-tea;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#861316;}
p.bl-jtitle-rcpsychsd, li.bl-jtitle-rcpsychsd, div.bl-jtitle-rcpsychsd
	{mso-style-name:bl-jtitle-rcpsychsd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#44448A;}
p.bl-jtitle-npgopen, li.bl-jtitle-npgopen, div.bl-jtitle-npgopen
	{mso-style-name:bl-jtitle-npgopen;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-maneyopen, li.bl-jtitle-maneyopen, div.bl-jtitle-maneyopen
	{mso-style-name:bl-jtitle-maneyopen;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-bmjgroup, li.bl-jtitle-bmjgroup, div.bl-jtitle-bmjgroup
	{mso-style-name:bl-jtitle-bmjgroup;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#003366;}
p.bl-jtitle-clpt, li.bl-jtitle-clpt, div.bl-jtitle-clpt
	{mso-style-name:bl-jtitle-clpt;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-nihpa-wiley, li.bl-jtitle-nihpa-wiley, div.bl-jtitle-nihpa-wiley
	{mso-style-name:bl-jtitle-nihpa-wiley;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-rsmsd, li.bl-jtitle-rsmsd, div.bl-jtitle-rsmsd
	{mso-style-name:bl-jtitle-rsmsd;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.bl-jtitle-hogrefesd, li.bl-jtitle-hogrefesd, div.bl-jtitle-hogrefesd
	{mso-style-name:bl-jtitle-hogrefesd;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#025490;}
p.mp-outer, li.mp-outer, div.mp-outer
	{mso-style-name:mp-outer;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mp-outerdiv, li.mp-outerdiv, div.mp-outerdiv
	{mso-style-name:mp-outer>div;
	margin:1.5pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.toc-highlight1, li.toc-highlight1, div.toc-highlight1
	{mso-style-name:toc-highlight1;
	margin-right:0in;
	margin-left:0in;
	background:#FFFFD0;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.toc-highlight2, li.toc-highlight2, div.toc-highlight2
	{mso-style-name:toc-highlight2;
	margin-right:0in;
	margin-left:0in;
	background:#ACE4FF;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.toc-hl-inaugural, li.toc-hl-inaugural, div.toc-hl-inaugural
	{mso-style-name:toc-hl-inaugural;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#E64A00;}
p.courtesy-note, li.courtesy-note, div.courtesy-note
	{mso-style-name:courtesy-note;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.footer, li.footer, div.footer
	{mso-style-name:footer;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.suppmat, li.suppmat, div.suppmat
	{mso-style-name:suppmat;
	margin-top:8.3pt;
	margin-right:0in;
	margin-bottom:8.3pt;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.aligncenter, li.aligncenter, div.aligncenter
	{mso-style-name:align_center;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mul-switcher, li.mul-switcher, div.mul-switcher
	{mso-style-name:mul-switcher;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.strong, li.strong, div.strong
	{mso-style-name:strong;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.red, li.red, div.red
	{mso-style-name:red;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:red;}
p.navigator, li.navigator, div.navigator
	{mso-style-name:navigator;
	margin-top:15.0pt;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F6F6F6;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.summary, li.summary, div.summary
	{mso-style-name:summary;
	margin-top:15.0pt;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.head1a, li.head1a, div.head1a
	{mso-style-name:head1a;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-header, li.navigator-header, div.navigator-header
	{mso-style-name:navigator-header;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-footer, li.navigator-footer, div.navigator-footer
	{mso-style-name:navigator-footer;
	margin-top:7.5pt;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-bar, li.navigator-bar, div.navigator-bar
	{mso-style-name:navigator-bar;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-page, li.navigator-page, div.navigator-page
	{mso-style-name:navigator-page;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.navigator-bar-table, li.navigator-bar-table, div.navigator-bar-table
	{mso-style-name:navigator-bar-table;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.section-with-images-on-the-same-page, li.section-with-images-on-the-same-page, div.section-with-images-on-the-same-page
	{mso-style-name:section-with-images-on-the-same-page;
	margin-top:15.0pt;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.main-archive-list-of-volumes, li.main-archive-list-of-volumes, div.main-archive-list-of-volumes
	{mso-style-name:main-archive-list-of-volumes;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.archive-header, li.archive-header, div.archive-header
	{mso-style-name:archive-header;
	margin-right:0in;
	margin-bottom:7.5pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.journal-block-title, li.journal-block-title, div.journal-block-title
	{mso-style-name:journal-block-title;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#CCD8E4;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:black;
	font-weight:bold;}
p.vol-year-cell, li.vol-year-cell, div.vol-year-cell
	{mso-style-name:vol-year-cell;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#CCD8E4;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:black;
	font-weight:bold;}
p.issue-block, li.issue-block, div.issue-block
	{mso-style-name:issue-block;
	margin-right:0in;
	margin-left:0in;
	background:#8CACCC;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.iss-dark-row, li.iss-dark-row, div.iss-dark-row
	{mso-style-name:iss-dark-row;
	margin-right:0in;
	margin-left:0in;
	background:#EFF1F3;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.iss-light-row, li.iss-light-row, div.iss-light-row
	{mso-style-name:iss-light-row;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.iss-cell, li.iss-cell, div.iss-cell
	{mso-style-name:iss-cell;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.vol-cell, li.vol-cell, div.vol-cell
	{mso-style-name:vol-cell;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.arc-issue, li.arc-issue, div.arc-issue
	{mso-style-name:arc-issue;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#0055AA;}
p.large-thumb-canvas, li.large-thumb-canvas, div.large-thumb-canvas
	{mso-style-name:large-thumb-canvas;
	margin:8.5pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#444444;
	display:none;}
p.co, li.co, div.co
	{mso-style-name:co;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.co-default, li.co-default, div.co-default
	{mso-style-name:co-default;
	margin:8.5pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#444444;}
p.large-thumb-canvas-1, li.large-thumb-canvas-1, div.large-thumb-canvas-1
	{mso-style-name:large-thumb-canvas-1;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.co-inner, li.co-inner, div.co-inner
	{mso-style-name:co-inner;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.in-progress, li.in-progress, div.in-progress
	{mso-style-name:in-progress;
	margin:1.5pt;
	background:#444444;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.large-thumb, li.large-thumb, div.large-thumb
	{mso-style-name:large-thumb;
	margin:1.5pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.small-thumb-canvas, li.small-thumb-canvas, div.small-thumb-canvas
	{mso-style-name:small-thumb-canvas;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.small-thumb, li.small-thumb, div.small-thumb
	{mso-style-name:small-thumb;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.figpopup-sensitive-area, li.figpopup-sensitive-area, div.figpopup-sensitive-area
	{mso-style-name:figpopup-sensitive-area;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.print-view, li.print-view, div.print-view
	{mso-style-name:print-view;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.citationexporter-header, li.citationexporter-header, div.citationexporter-header
	{mso-style-name:citationexporter-header;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-style:italic;}
p.citationexporter-footer, li.citationexporter-footer, div.citationexporter-footer
	{mso-style-name:citationexporter-footer;
	margin-top:12.0pt;
	margin-right:0in;
	margin-bottom:12.0pt;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxpreview, li.mathjaxpreview, div.mathjaxpreview
	{mso-style-name:mathjax_preview;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#888888;}
p.mathjaxerror, li.mathjaxerror, div.mathjaxerror
	{mso-style-name:mathjax_error;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CC0000;
	font-style:italic;}
p.mathjaxmenu, li.mathjaxmenu, div.mathjaxmenu
	{mso-style-name:mathjax_menu;
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:black;}
p.mathjaxmenuitem, li.mathjaxmenuitem, div.mathjaxmenuitem
	{mso-style-name:mathjax_menuitem;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxmenuarrow, li.mathjaxmenuarrow, div.mathjaxmenuarrow
	{mso-style-name:mathjax_menuarrow;
	margin-right:0in;
	margin-left:0in;
	font-size:9.0pt;
	font-family:"Arial Unicode MS","sans-serif";
	color:#666666;}
p.mathjaxmenucheck, li.mathjaxmenucheck, div.mathjaxmenucheck
	{mso-style-name:mathjax_menucheck;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial Unicode MS","sans-serif";}
p.mathjaxmenulabel, li.mathjaxmenulabel, div.mathjaxmenulabel
	{mso-style-name:mathjax_menulabel;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-style:italic;}
p.mathjaxmenurule, li.mathjaxmenurule, div.mathjaxmenurule
	{mso-style-name:mathjax_menurule;
	margin-top:3.0pt;
	margin-right:.75pt;
	margin-bottom:0in;
	margin-left:.75pt;
	margin-bottom:.0001pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxmenuclose, li.mathjaxmenuclose, div.mathjaxmenuclose
	{mso-style-name:mathjax_menuclose;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:18.0pt;
	font-family:"Courier New";
	color:#F0F0F0;}
p.print-log, li.print-log, div.print-log
	{mso-style-name:print-log;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-header, li.ui-accordion-header, div.ui-accordion-header
	{mso-style-name:ui-accordion-header;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-icons, li.ui-accordion-icons, div.ui-accordion-icons
	{mso-style-name:ui-accordion-icons;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-content, li.ui-accordion-content, div.ui-accordion-content
	{mso-style-name:ui-accordion-content;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text, li.ui-button-text, div.ui-button-text
	{mso-style-name:ui-button-text;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header, li.ui-datepicker-header, div.ui-datepicker-header
	{mso-style-name:ui-datepicker-header;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-next, li.ui-datepicker-next, div.ui-datepicker-next
	{mso-style-name:ui-datepicker-next;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-prev, li.ui-datepicker-prev, div.ui-datepicker-prev
	{mso-style-name:ui-datepicker-prev;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-title, li.ui-datepicker-title, div.ui-datepicker-title
	{mso-style-name:ui-datepicker-title;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-buttonpane, li.ui-datepicker-buttonpane, div.ui-datepicker-buttonpane
	{mso-style-name:ui-datepicker-buttonpane;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-group, li.ui-datepicker-group, div.ui-datepicker-group
	{mso-style-name:ui-datepicker-group;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-title, li.ui-dialog-title, div.ui-dialog-title
	{mso-style-name:ui-dialog-title;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-buttonpane, li.ui-dialog-buttonpane, div.ui-dialog-buttonpane
	{mso-style-name:ui-dialog-buttonpane;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu-item, li.ui-menu-item, div.ui-menu-item
	{mso-style-name:ui-menu-item;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu-divider, li.ui-menu-divider, div.ui-menu-divider
	{mso-style-name:ui-menu-divider;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-value, li.ui-progressbar-value, div.ui-progressbar-value
	{mso-style-name:ui-progressbar-value;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-overlay, li.ui-progressbar-overlay, div.ui-progressbar-overlay
	{mso-style-name:ui-progressbar-overlay;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-handle, li.ui-slider-handle, div.ui-slider-handle
	{mso-style-name:ui-slider-handle;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-range, li.ui-slider-range, div.ui-slider-range
	{mso-style-name:ui-slider-range;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-nav, li.ui-tabs-nav, div.ui-tabs-nav
	{mso-style-name:ui-tabs-nav;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-panel, li.ui-tabs-panel, div.ui-tabs-panel
	{mso-style-name:ui-tabs-panel;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-hide, li.ui-tabs-hide, div.ui-tabs-hide
	{mso-style-name:ui-tabs-hide;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-titlebar-close, li.ui-dialog-titlebar-close, div.ui-dialog-titlebar-close
	{mso-style-name:ui-dialog-titlebar-close;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-content, li.ui-dialog-content, div.ui-dialog-content
	{mso-style-name:ui-dialog-content;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiautocomplete-link-pref-right, li.ui-ncbiautocomplete-link-pref-right, div.ui-ncbiautocomplete-link-pref-right
	{mso-style-name:ui-ncbiautocomplete-link-pref-right;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-primary, li.ui-button-icon-primary, div.ui-button-icon-primary
	{mso-style-name:ui-button-icon-primary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-secondary, li.ui-button-icon-secondary, div.ui-button-icon-secondary
	{mso-style-name:ui-button-icon-secondary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.prev, li.prev, div.prev
	{mso-style-name:prev;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.next, li.next, div.next
	{mso-style-name:next;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-select-row-count, li.ui-ncbigrid-select-row-count, div.ui-ncbigrid-select-row-count
	{mso-style-name:ui-ncbigrid-select-row-count;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibasicmenulia, li.ui-ncbibasicmenulia, div.ui-ncbibasicmenulia
	{mso-style-name:ui-ncbibasicmenu>li>a;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbimenu-item-leaf, li.ui-ncbimenu-item-leaf, div.ui-ncbimenu-item-leaf
	{mso-style-name:ui-ncbimenu-item-leaf;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.brieflinkpop, li.brieflinkpop, div.brieflinkpop
	{mso-style-name:brieflinkpop;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.star, li.star, div.star
	{mso-style-name:star;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbisetswitch, li.jig-ncbisetswitch, div.jig-ncbisetswitch
	{mso-style-name:jig-ncbisetswitch;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbisetswitch-button, li.ui-ncbisetswitch-button, div.ui-ncbisetswitch-button
	{mso-style-name:ui-ncbisetswitch-button;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbisetswitch-options, li.ui-ncbisetswitch-options, div.ui-ncbisetswitch-options
	{mso-style-name:ui-ncbisetswitch-options;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.boxed-text-box, li.boxed-text-box, div.boxed-text-box
	{mso-style-name:boxed-text-box;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.cell-from, li.cell-from, div.cell-from
	{mso-style-name:cell-from;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.cell-citation, li.cell-citation, div.cell-citation
	{mso-style-name:cell-citation;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.figpopup, li.figpopup, div.figpopup
	{mso-style-name:figpopup;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.button, li.button, div.button
	{mso-style-name:button;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.retraction, li.retraction, div.retraction
	{mso-style-name:retraction;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxhoverarrow, li.mathjaxhoverarrow, div.mathjaxhoverarrow
	{mso-style-name:mathjax_hover_arrow;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.pbody, li.pbody, div.pbody
	{mso-style-name:pbody;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-box, li.page-box, div.page-box
	{mso-style-name:page-box;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-box-wide, li.page-box-wide, div.page-box-wide
	{mso-style-name:page-box-wide;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.nomaxwidth, li.nomaxwidth, div.nomaxwidth
	{mso-style-name:no_max_width;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.f, li.f, div.f
	{mso-style-name:f;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.l, li.l, div.l
	{mso-style-name:l;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-header-icon, li.ui-accordion-header-icon, div.ui-accordion-header-icon
	{mso-style-name:ui-accordion-header-icon;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectmenu-optgroup, li.ui-selectmenu-optgroup, div.ui-selectmenu-optgroup
	{mso-style-name:ui-selectmenu-optgroup;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-anchor, li.ui-tabs-anchor, div.ui-tabs-anchor
	{mso-style-name:ui-tabs-anchor;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibutton-submit, li.ui-ncbibutton-submit, div.ui-ncbibutton-submit
	{mso-style-name:ui-ncbibutton-submit;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibutton-cancel, li.ui-ncbibutton-cancel, div.ui-ncbibutton-cancel
	{mso-style-name:ui-ncbibutton-cancel;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ltd-hover, li.ltd-hover, div.ltd-hover
	{mso-style-name:ltd-hover;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.warn, li.warn, div.warn
	{mso-style-name:warn;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.notice, li.notice, div.notice
	{mso-style-name:notice;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.content, li.content, div.content
	{mso-style-name:content;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.onelinesource, li.onelinesource, div.onelinesource
	{mso-style-name:one_line_source;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tertiary, li.tertiary, div.tertiary
	{mso-style-name:tertiary;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxhoverframe, li.mathjaxhoverframe, div.mathjaxhoverframe
	{mso-style-name:mathjax_hover_frame;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
span.other-issues
	{mso-style-name:other-issues;}
span.underline
	{mso-style-name:underline;}
span.double-underline
	{mso-style-name:double-underline;}
span.bold-double-underline
	{mso-style-name:bold-double-underline;}
span.ui-icon1
	{mso-style-name:ui-icon1;}
span.ui-selectmenu-text
	{mso-style-name:ui-selectmenu-text;}
span.pagelink
	{mso-style-name:page_link;}
span.ui-icon-plus-minus-big
	{mso-style-name:ui-icon-plus-minus-big;}
span.ui-icon-plus-minus-big-open
	{mso-style-name:ui-icon-plus-minus-big-open;}
span.collapsabletbodyicon
	{mso-style-name:collapsabletbodyicon;}
p.ui-accordion-header1, li.ui-accordion-header1, div.ui-accordion-header1
	{mso-style-name:ui-accordion-header1;
	margin-top:1.5pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-icons1, li.ui-accordion-icons1, div.ui-accordion-icons1
	{mso-style-name:ui-accordion-icons1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-icons2, li.ui-accordion-icons2, div.ui-accordion-icons2
	{mso-style-name:ui-accordion-icons2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-header-icon1, li.ui-accordion-header-icon1, div.ui-accordion-header-icon1
	{mso-style-name:ui-accordion-header-icon1;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-accordion-content1, li.ui-accordion-content1, div.ui-accordion-content1
	{mso-style-name:ui-accordion-content1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text1, li.ui-button-text1, div.ui-button-text1
	{mso-style-name:ui-button-text1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text2, li.ui-button-text2, div.ui-button-text2
	{mso-style-name:ui-button-text2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text3, li.ui-button-text3, div.ui-button-text3
	{mso-style-name:ui-button-text3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon2, li.ui-icon2, div.ui-icon2
	{mso-style-name:ui-icon2;
	margin-top:0in;
	margin-right:0in;
	margin-left:-6.0pt;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button1, li.ui-button1, div.ui-button1
	{mso-style-name:ui-button1;
	margin-right:-.05in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header1, li.ui-datepicker-header1, div.ui-datepicker-header1
	{mso-style-name:ui-datepicker-header1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-next1, li.ui-datepicker-next1, div.ui-datepicker-next1
	{mso-style-name:ui-datepicker-next1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-prev1, li.ui-datepicker-prev1, div.ui-datepicker-prev1
	{mso-style-name:ui-datepicker-prev1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-title1, li.ui-datepicker-title1, div.ui-datepicker-title1
	{mso-style-name:ui-datepicker-title1;
	margin-top:0in;
	margin-right:27.6pt;
	margin-bottom:0in;
	margin-left:27.6pt;
	margin-bottom:.0001pt;
	text-align:center;
	line-height:21.6pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-buttonpane1, li.ui-datepicker-buttonpane1, div.ui-datepicker-buttonpane1
	{mso-style-name:ui-datepicker-buttonpane1;
	margin-top:8.4pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-group1, li.ui-datepicker-group1, div.ui-datepicker-group1
	{mso-style-name:ui-datepicker-group1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-group2, li.ui-datepicker-group2, div.ui-datepicker-group2
	{mso-style-name:ui-datepicker-group2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-group3, li.ui-datepicker-group3, div.ui-datepicker-group3
	{mso-style-name:ui-datepicker-group3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header2, li.ui-datepicker-header2, div.ui-datepicker-header2
	{mso-style-name:ui-datepicker-header2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header3, li.ui-datepicker-header3, div.ui-datepicker-header3
	{mso-style-name:ui-datepicker-header3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-buttonpane2, li.ui-datepicker-buttonpane2, div.ui-datepicker-buttonpane2
	{mso-style-name:ui-datepicker-buttonpane2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-buttonpane3, li.ui-datepicker-buttonpane3, div.ui-datepicker-buttonpane3
	{mso-style-name:ui-datepicker-buttonpane3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header4, li.ui-datepicker-header4, div.ui-datepicker-header4
	{mso-style-name:ui-datepicker-header4;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-datepicker-header5, li.ui-datepicker-header5, div.ui-datepicker-header5
	{mso-style-name:ui-datepicker-header5;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-title1, li.ui-dialog-title1, div.ui-dialog-title1
	{mso-style-name:ui-dialog-title1;
	margin-top:1.2pt;
	margin-right:12.0pt;
	margin-bottom:2.4pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-buttonpane1, li.ui-dialog-buttonpane1, div.ui-dialog-buttonpane1
	{mso-style-name:ui-dialog-buttonpane1;
	margin-top:6.0pt;
	margin-right:0in;
	margin-left:0in;
	background:whitesmoke;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu-item1, li.ui-menu-item1, div.ui-menu-item1
	{mso-style-name:ui-menu-item1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-menu-divider1, li.ui-menu-divider1, div.ui-menu-divider1
	{mso-style-name:ui-menu-divider1;
	margin-top:3.75pt;
	margin-right:0in;
	margin-bottom:3.75pt;
	margin-left:0in;
	line-height:0%;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-active1, li.ui-state-active1, div.ui-state-active1
	{mso-style-name:ui-state-active1;
	margin-top:0in;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-focus1, li.ui-state-focus1, div.ui-state-focus1
	{mso-style-name:ui-state-focus1;
	margin-top:0in;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-menu-item2, li.ui-menu-item2, div.ui-menu-item2
	{mso-style-name:ui-menu-item2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon3, li.ui-icon3, div.ui-icon3
	{mso-style-name:ui-icon3;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-value1, li.ui-progressbar-value1, div.ui-progressbar-value1
	{mso-style-name:ui-progressbar-value1;
	margin-top:0in;
	margin-right:-.75pt;
	margin-bottom:0in;
	margin-left:-.75pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-overlay1, li.ui-progressbar-overlay1, div.ui-progressbar-overlay1
	{mso-style-name:ui-progressbar-overlay1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-progressbar-value2, li.ui-progressbar-value2, div.ui-progressbar-value2
	{mso-style-name:ui-progressbar-value2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-handle1, li.ui-resizable-handle1, div.ui-resizable-handle1
	{mso-style-name:ui-resizable-handle1;
	margin-right:0in;
	margin-left:0in;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-resizable-handle2, li.ui-resizable-handle2, div.ui-resizable-handle2
	{mso-style-name:ui-resizable-handle2;
	margin-right:0in;
	margin-left:0in;
	font-size:1.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-menu1, li.ui-menu1, div.ui-menu1
	{mso-style-name:ui-menu1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-selectmenu-optgroup1, li.ui-selectmenu-optgroup1, div.ui-selectmenu-optgroup1
	{mso-style-name:ui-selectmenu-optgroup1;
	margin-top:6.0pt;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
span.ui-icon4
	{mso-style-name:ui-icon4;}
span.ui-selectmenu-text1
	{mso-style-name:ui-selectmenu-text1;}
p.ui-slider-handle1, li.ui-slider-handle1, div.ui-slider-handle1
	{mso-style-name:ui-slider-handle1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-range1, li.ui-slider-range1, div.ui-slider-range1
	{mso-style-name:ui-slider-range1;
	margin-right:0in;
	margin-left:0in;
	font-size:8.5pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-handle2, li.ui-slider-handle2, div.ui-slider-handle2
	{mso-style-name:ui-slider-handle2;
	margin-right:0in;
	margin-left:-.1in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-handle3, li.ui-slider-handle3, div.ui-slider-handle3
	{mso-style-name:ui-slider-handle3;
	margin-right:0in;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-slider-range2, li.ui-slider-range2, div.ui-slider-range2
	{mso-style-name:ui-slider-range2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon5, li.ui-icon5, div.ui-icon5
	{mso-style-name:ui-icon5;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-anchor1, li.ui-tabs-anchor1, div.ui-tabs-anchor1
	{mso-style-name:ui-tabs-anchor1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tooltip1, li.ui-tooltip1, div.ui-tooltip1
	{mso-style-name:ui-tooltip1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-widget1, li.ui-widget1, div.ui-widget1
	{mso-style-name:ui-widget1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.ui-state-default1, li.ui-state-default1, div.ui-state-default1
	{mso-style-name:ui-state-default1;
	margin-right:0in;
	margin-left:0in;
	background:#E6E6E6;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#555555;}
p.ui-state-default2, li.ui-state-default2, div.ui-state-default2
	{mso-style-name:ui-state-default2;
	margin-right:0in;
	margin-left:0in;
	background:#E6E6E6;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#555555;}
p.ui-state-focus2, li.ui-state-focus2, div.ui-state-focus2
	{mso-style-name:ui-state-focus2;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-hover1, li.ui-state-hover1, div.ui-state-hover1
	{mso-style-name:ui-state-hover1;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-focus3, li.ui-state-focus3, div.ui-state-focus3
	{mso-style-name:ui-state-focus3;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-hover2, li.ui-state-hover2, div.ui-state-hover2
	{mso-style-name:ui-state-hover2;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-active2, li.ui-state-active2, div.ui-state-active2
	{mso-style-name:ui-state-active2;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-active3, li.ui-state-active3, div.ui-state-active3
	{mso-style-name:ui-state-active3;
	margin-right:0in;
	margin-left:0in;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-state-highlight1, li.ui-state-highlight1, div.ui-state-highlight1
	{mso-style-name:ui-state-highlight1;
	margin-right:0in;
	margin-left:0in;
	background:#FBF9EE;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#363636;}
p.ui-state-highlight2, li.ui-state-highlight2, div.ui-state-highlight2
	{mso-style-name:ui-state-highlight2;
	margin-right:0in;
	margin-left:0in;
	background:#FBF9EE;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#363636;}
p.ui-state-error1, li.ui-state-error1, div.ui-state-error1
	{mso-style-name:ui-state-error1;
	margin-right:0in;
	margin-left:0in;
	background:#FEF1EC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-state-error2, li.ui-state-error2, div.ui-state-error2
	{mso-style-name:ui-state-error2;
	margin-right:0in;
	margin-left:0in;
	background:#FEF1EC;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-state-error-text1, li.ui-state-error-text1, div.ui-state-error-text1
	{mso-style-name:ui-state-error-text1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-state-error-text2, li.ui-state-error-text2, div.ui-state-error-text2
	{mso-style-name:ui-state-error-text2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#CD0A0A;}
p.ui-priority-primary1, li.ui-priority-primary1, div.ui-priority-primary1
	{mso-style-name:ui-priority-primary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.ui-priority-primary2, li.ui-priority-primary2, div.ui-priority-primary2
	{mso-style-name:ui-priority-primary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.ui-priority-secondary1, li.ui-priority-secondary1, div.ui-priority-secondary1
	{mso-style-name:ui-priority-secondary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-priority-secondary2, li.ui-priority-secondary2, div.ui-priority-secondary2
	{mso-style-name:ui-priority-secondary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-disabled1, li.ui-state-disabled1, div.ui-state-disabled1
	{mso-style-name:ui-state-disabled1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-disabled2, li.ui-state-disabled2, div.ui-state-disabled2
	{mso-style-name:ui-state-disabled2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon6, li.ui-icon6, div.ui-icon6
	{mso-style-name:ui-icon6;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon7, li.ui-icon7, div.ui-icon7
	{mso-style-name:ui-icon7;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon8, li.ui-icon8, div.ui-icon8
	{mso-style-name:ui-icon8;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon9, li.ui-icon9, div.ui-icon9
	{mso-style-name:ui-icon9;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon10, li.ui-icon10, div.ui-icon10
	{mso-style-name:ui-icon10;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon11, li.ui-icon11, div.ui-icon11
	{mso-style-name:ui-icon11;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon12, li.ui-icon12, div.ui-icon12
	{mso-style-name:ui-icon12;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon13, li.ui-icon13, div.ui-icon13
	{mso-style-name:ui-icon13;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon14, li.ui-icon14, div.ui-icon14
	{mso-style-name:ui-icon14;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-nav1, li.ui-tabs-nav1, div.ui-tabs-nav1
	{mso-style-name:ui-tabs-nav1;
	margin:0in;
	margin-bottom:.0001pt;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.tertiary1, li.tertiary1, div.tertiary1
	{mso-style-name:tertiary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#666666;}
p.tertiary2, li.tertiary2, div.tertiary2
	{mso-style-name:tertiary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#985735;}
p.ui-tabs-panel1, li.ui-tabs-panel1, div.ui-tabs-panel1
	{mso-style-name:ui-tabs-panel1;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-tabs-hide1, li.ui-tabs-hide1, div.ui-tabs-hide1
	{mso-style-name:ui-tabs-hide1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	display:none;}
p.ui-dialog-titlebar1, li.ui-dialog-titlebar1, div.ui-dialog-titlebar1
	{mso-style-name:ui-dialog-titlebar1;
	margin-right:0in;
	margin-left:0in;
	background:#3E72A6;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:white;}
p.ui-dialog-titlebar-close1, li.ui-dialog-titlebar-close1, div.ui-dialog-titlebar-close1
	{mso-style-name:ui-dialog-titlebar-close1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-dialog-content1, li.ui-dialog-content1, div.ui-dialog-content1
	{mso-style-name:ui-dialog-content1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-resizable-se1, li.ui-resizable-se1, div.ui-resizable-se1
	{mso-style-name:ui-resizable-se1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon15, li.ui-icon15, div.ui-icon15
	{mso-style-name:ui-icon15;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-state-hover3, li.ui-state-hover3, div.ui-state-hover3
	{mso-style-name:ui-state-hover3;
	margin-right:0in;
	margin-left:0in;
	background:#DADADA;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#212121;}
p.ui-ncbibutton-submit1, li.ui-ncbibutton-submit1, div.ui-ncbibutton-submit1
	{mso-style-name:ui-ncbibutton-submit1;
	margin-right:6.55pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbibutton-cancel1, li.ui-ncbibutton-cancel1, div.ui-ncbibutton-cancel1
	{mso-style-name:ui-ncbibutton-cancel1;
	margin-right:0in;
	margin-left:0in;
	line-height:22.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#2F4A8B;}
p.ui-button-text4, li.ui-button-text4, div.ui-button-text4
	{mso-style-name:ui-button-text4;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbiautocomplete-link-pref-right1, li.ui-ncbiautocomplete-link-pref-right1, div.ui-ncbiautocomplete-link-pref-right1
	{mso-style-name:ui-ncbiautocomplete-link-pref-right1;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text5, li.ui-button-text5, div.ui-button-text5
	{mso-style-name:ui-button-text5;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text6, li.ui-button-text6, div.ui-button-text6
	{mso-style-name:ui-button-text6;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text7, li.ui-button-text7, div.ui-button-text7
	{mso-style-name:ui-button-text7;
	margin-right:0in;
	margin-left:0in;
	text-indent:595.95pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text8, li.ui-button-text8, div.ui-button-text8
	{mso-style-name:ui-button-text8;
	margin-right:0in;
	margin-left:0in;
	text-indent:595.95pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text9, li.ui-button-text9, div.ui-button-text9
	{mso-style-name:ui-button-text9;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-text10, li.ui-button-text10, div.ui-button-text10
	{mso-style-name:ui-button-text10;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon16, li.ui-icon16, div.ui-icon16
	{mso-style-name:ui-icon16;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon17, li.ui-icon17, div.ui-icon17
	{mso-style-name:ui-icon17;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon18, li.ui-icon18, div.ui-icon18
	{mso-style-name:ui-icon18;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon19, li.ui-icon19, div.ui-icon19
	{mso-style-name:ui-icon19;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon20, li.ui-icon20, div.ui-icon20
	{mso-style-name:ui-icon20;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon21, li.ui-icon21, div.ui-icon21
	{mso-style-name:ui-icon21;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-primary1, li.ui-button-icon-primary1, div.ui-button-icon-primary1
	{mso-style-name:ui-button-icon-primary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-primary2, li.ui-button-icon-primary2, div.ui-button-icon-primary2
	{mso-style-name:ui-button-icon-primary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-primary3, li.ui-button-icon-primary3, div.ui-button-icon-primary3
	{mso-style-name:ui-button-icon-primary3;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-secondary1, li.ui-button-icon-secondary1, div.ui-button-icon-secondary1
	{mso-style-name:ui-button-icon-secondary1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-button-icon-secondary2, li.ui-button-icon-secondary2, div.ui-button-icon-secondary2
	{mso-style-name:ui-button-icon-secondary2;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-paged-pagecontrol1, li.ui-ncbigrid-paged-pagecontrol1, div.ui-ncbigrid-paged-pagecontrol1
	{mso-style-name:ui-ncbigrid-paged-pagecontrol1;
	margin-top:0in;
	margin-right:0in;
	margin-left:0in;
	text-align:right;
	font-size:11.0pt;
	font-family:"Times New Roman","serif";}
p.prev1, li.prev1, div.prev1
	{mso-style-name:prev1;
	margin-right:.1in;
	margin-left:2.4pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.next1, li.next1, div.next1
	{mso-style-name:next1;
	margin-right:2.4pt;
	margin-left:.1in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbigrid-select-row-count1, li.ui-ncbigrid-select-row-count1, div.ui-ncbigrid-select-row-count1
	{mso-style-name:ui-ncbigrid-select-row-count1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
span.pagelink1
	{mso-style-name:page_link1;
	color:#CCCCCC;}
span.collapsabletbodyicon1
	{mso-style-name:collapsabletbodyicon1;}
span.ui-icon-plus-minus-big1
	{mso-style-name:ui-icon-plus-minus-big1;}
span.ui-icon-plus-minus-big-open1
	{mso-style-name:ui-icon-plus-minus-big-open1;}
p.ui-ncbigrid-outer-div1, li.ui-ncbigrid-outer-div1, div.ui-ncbigrid-outer-div1
	{mso-style-name:ui-ncbigrid-outer-div1;
	margin:0in;
	margin-bottom:.0001pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbimenu-item-leaf1, li.ui-ncbimenu-item-leaf1, div.ui-ncbimenu-item-leaf1
	{mso-style-name:ui-ncbimenu-item-leaf1;
	margin-top:0in;
	margin-right:9.0pt;
	margin-bottom:0in;
	margin-left:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.brieflinkpop1, li.brieflinkpop1, div.brieflinkpop1
	{mso-style-name:brieflinkpop1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
span.ui-icon-plus-minus-big2
	{mso-style-name:ui-icon-plus-minus-big2;}
span.ui-icon-plus-minus-big-open2
	{mso-style-name:ui-icon-plus-minus-big-open2;}
span.ui-icon22
	{mso-style-name:ui-icon22;}
span.ui-icon23
	{mso-style-name:ui-icon23;}
p.star1, li.star1, div.star1
	{mso-style-name:star1;
	margin-right:7.4pt;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.jig-ncbisetswitch1, li.jig-ncbisetswitch1, div.jig-ncbisetswitch1
	{mso-style-name:jig-ncbisetswitch1;
	margin-right:0in;
	margin-left:0in;
	line-height:14.75pt;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#333333;}
p.ui-ncbisetswitch-button1, li.ui-ncbisetswitch-button1, div.ui-ncbisetswitch-button1
	{mso-style-name:ui-ncbisetswitch-button1;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon24, li.ui-icon24, div.ui-icon24
	{mso-style-name:ui-icon24;
	margin:5.55pt;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ltd-hover1, li.ltd-hover1, div.ltd-hover1
	{mso-style-name:ltd-hover1;
	margin-right:0in;
	margin-left:0in;
	background:#E8E8E8;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-icon25, li.ui-icon25, div.ui-icon25
	{mso-style-name:ui-icon25;
	margin-right:0in;
	margin-left:0in;
	text-indent:367.15pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.ui-ncbisetswitch-options1, li.ui-ncbisetswitch-options1, div.ui-ncbisetswitch-options1
	{mso-style-name:ui-ncbisetswitch-options1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.pbody1, li.pbody1, div.pbody1
	{mso-style-name:pbody1;
	margin-top:0in;
	margin-right:16.6pt;
	margin-bottom:0in;
	margin-left:16.6pt;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-box1, li.page-box1, div.page-box1
	{mso-style-name:page-box1;
	margin-top:16.6pt;
	margin-right:0in;
	margin-bottom:16.6pt;
	margin-left:0in;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.page-box-wide1, li.page-box-wide1, div.page-box-wide1
	{mso-style-name:page-box-wide1;
	margin-top:16.6pt;
	margin-right:0in;
	margin-bottom:16.6pt;
	margin-left:0in;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.nomaxwidth1, li.nomaxwidth1, div.nomaxwidth1
	{mso-style-name:no_max_width1;
	margin-right:0in;
	margin-left:0in;
	background:white;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.content1, li.content1, div.content1
	{mso-style-name:content1;
	margin:16.6pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.boxed-text-box1, li.boxed-text-box1, div.boxed-text-box1
	{mso-style-name:boxed-text-box1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.f1, li.f1, div.f1
	{mso-style-name:f1;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.l1, li.l1, div.l1
	{mso-style-name:l1;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.cell-from1, li.cell-from1, div.cell-from1
	{mso-style-name:cell-from1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	font-weight:bold;}
p.cell-citation1, li.cell-citation1, div.cell-citation1
	{mso-style-name:cell-citation1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.figpopup1, li.figpopup1, div.figpopup1
	{mso-style-name:figpopup1;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.button1, li.button1, div.button1
	{mso-style-name:button1;
	margin:0in;
	margin-bottom:.0001pt;
	text-align:center;
	background:white;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";
	color:#336699;}
p.retraction1, li.retraction1, div.retraction1
	{mso-style-name:retraction1;
	margin-right:0in;
	margin-left:0in;
	background:red;
	font-size:12.0pt;
	font-family:"Helvetica","sans-serif";
	color:#F0F0F0;}
p.warn1, li.warn1, div.warn1
	{mso-style-name:warn1;
	margin:0in;
	margin-bottom:.0001pt;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.notice1, li.notice1, div.notice1
	{mso-style-name:notice1;
	margin-right:0in;
	margin-left:0in;
	font-size:16.5pt;
	font-family:"Times New Roman","serif";}
p.arrowtab1, li.arrowtab1, div.arrowtab1
	{mso-style-name:arrowtab1;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F8F8F8;
	border:none;
	padding:0in;
	font-size:12.0pt;
	font-family:"Arial","sans-serif";}
p.thistab1, li.thistab1, div.thistab1
	{mso-style-name:thistab1;
	margin-right:0in;
	margin-left:0in;
	text-align:center;
	background:#F6F6F6;
	border:none;
	padding:0in;
	font-size:9.5pt;
	font-family:"Arial","sans-serif";
	font-weight:bold;}
p.onelinesource1, li.onelinesource1, div.onelinesource1
	{mso-style-name:one_line_source1;
	margin-right:0in;
	margin-left:0in;
	background:#E0E0E0;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.mathjaxhoverarrow1, li.mathjaxhoverarrow1, div.mathjaxhoverarrow1
	{mso-style-name:mathjax_hover_arrow1;
	margin-right:0in;
	margin-left:0in;
	border:none;
	padding:0in;
	font-size:7.0pt;
	font-family:"Courier New";
	color:#F0F0F0;}
p.mathjaxmenuarrow1, li.mathjaxmenuarrow1, div.mathjaxmenuarrow1
	{mso-style-name:mathjax_menuarrow1;
	margin-right:0in;
	margin-left:0in;
	font-size:9.0pt;
	font-family:"Arial Unicode MS","sans-serif";
	color:white;}
span.cit
	{mso-style-name:cit;}
span.fm-vol-iss-date
	{mso-style-name:fm-vol-iss-date;}
span.doi1
	{mso-style-name:doi1;}
span.fm-citation-ids-label
	{mso-style-name:fm-citation-ids-label;}
span.fm-role
	{mso-style-name:fm-role;}
span.before-email-separator
	{mso-style-name:before-email-separator;}
span.email-label
	{mso-style-name:email-label;}
p.p, li.p, div.p
	{mso-style-name:p;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
p.fn, li.fn, div.fn
	{mso-style-name:fn;
	margin-right:0in;
	margin-left:0in;
	font-size:12.0pt;
	font-family:"Times New Roman","serif";}
span.citation
	{mso-style-name:citation;}
span.ref-journal
	{mso-style-name:ref-journal;}
span.ref-vol
	{mso-style-name:ref-vol;}
span.nowrap
	{mso-style-name:nowrap;}
span.acknowledgment-journal-title
	{mso-style-name:acknowledgment-journal-title;}
span.BalloonTextChar
	{mso-style-name:"Balloon Text Char";
	mso-style-link:"Balloon Text";
	font-family:"Tahoma","sans-serif";}
.MsoChpDefault
	{font-family:"Calibri","sans-serif";}
.MsoPapDefault
	{margin-bottom:10.0pt;
	line-height:115%;}
@page WordSection1
	{size:8.5in 11.0in;
	margin:1.0in 1.0in 1.0in 1.0in;}
div.WordSection1
	{page:WordSection1;}
 /* List Definitions */
 ol
	{margin-bottom:0in;}
ul
	{margin-bottom:0in;}
-->
</style>

</head>

<body lang=EN-US link=blue vlink=purple>

<div class=WordSection1>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PLoS
ONE. 2009; 4(5): e5563. </span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Published
online 2009 May 15. doi:&nbsp; <a
href="http://dx.doi.org/10.1371%2Fjournal.pone.0005563" target="pmc_ext">10.1371/journal.pone.0005563</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>PMCID:
PMC2680060</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:24.0pt;font-family:"Times New Roman","serif"'>Expression of a
Mutant p53 Results in an Age-Related Demographic Shift in Spontaneous Lung
Tumor Formation in Transgenic Mice</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Duan%20W%5Bauth%5D">Wenrui Duan</a>,<sup>1,2,*</sup>
<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Gao%20L%5Bauth%5D">Li Gao</a>,<sup>1,2</sup>
<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Wu%20X%5Bauth%5D">Xin Wu</a>,<sup>1,2</sup>
<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Hade%20EM%5Bauth%5D">Erinn M.
Hade</a>,<sup>1,3</sup> <a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Gao%20JX%5Bauth%5D">Jian-Xin Gao</a>,<sup>1,4</sup>
<a href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Ding%20H%5Bauth%5D">Haiming
Ding</a>,<sup>1,5</sup> <a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Barsky%20SH%5Bauth%5D">Sanford
H. Barsky</a>,<sup>1,4</sup> <a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Otterson%20GA%5Bauth%5D">Gregory
A. Otterson</a>,<sup>1,2</sup> and <a
href="http://www.ncbi.nlm.nih.gov/pubmed/?term=Villalona-Calero%20MA%5Bauth%5D">Miguel
A. Villalona-Calero</a><sup>1,2,6,*</sup></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Mikhail
V. Blagosklonny, Editor</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>1</span></sup><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";display:none'>Comprehensive Cancer Center, The Ohio
State University College of Medicine and Public Health, Columbus, Ohio, United
States of America</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>2</span></sup><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";display:none'>Department of Internal Medicine, The
Ohio State University College of Medicine and Public Health, Columbus, Ohio,
United States of America</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>3</span></sup><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";display:none'>The Center for Biostatistics, The Ohio
State University College of Medicine and Public Health, Columbus, Ohio, United
States of America</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>4</span></sup><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";display:none'>Department of Pathology, The Ohio State
University College of Medicine and Public Health, Columbus, Ohio, United States
of America</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>5</span></sup><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";display:none'>Department of Radiology, The Ohio State
University College of Medicine and Public Health, Columbus, Ohio, United States
of America</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><sup><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>6</span></sup><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif";display:none'>Department of Pharmacology, The Ohio
State University College of Medicine and Public Health, Columbus, Ohio, United
States of America</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>Ordway Research Institute, United States of America</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>* E-mail: <a href="mailto:dev@null">ude.cmuso@naud.iurneW</a>
(WD); Email: <a href="mailto:dev@null">ude.cmuso@anolalliv.leugim</a> (MAV-C)</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";display:none'>Conceived and
designed the experiments: WD LG GAO MAVC. Performed the experiments: WD LG XW
JXG HD. Analyzed the data: WD EMH JXG SHB. Wrote the paper: WD SHB GAO MAVC.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/">Author information
&#9658;</a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/">Article
notes &#9658;</a> <a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/">Copyright
and License information &#9658;</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'>Received 2009 Jan 6; Accepted 2009 Apr 18.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif";
display:none'><a href="http://www.ncbi.nlm.nih.gov/pmc/about/copyright.html">Copyright</a>
Duan et al. This is an open-access article distributed under the terms of the
Creative Commons Attribution License, which permits unrestricted use,
distribution, and reproduction in any medium, provided the original author and
source are credited.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>This
article has been <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/citedby/">cited by</a>
other articles in PMC.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif"'>Abstract</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Background</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Mutations in the P53 gene are
among the most common genetic abnormalities in human lung cancer. Codon 273 in
the sequence-specific DNA binding domain is one of the most frequently mutated
sites.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Methodology</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>To investigate the role of mutant
p<i>5</i>3 in lung tumorigenesis, a lung specific p53(273H) transgenic mouse
model was developed. Rates of lung cancer formation in the transgenic animals
and their littermates were evaluated by necropsy studies performed in
progressive age cohorts ranging from 4 to 24 months. <span style='background:
yellow'>In order to establish the influence of other common genetic
abnormalities in lung tumor formation in the animals, K-Ras gene mutation and
p16INK4a (p16) promoter methylation were evaluated in a total of 281 transgenic
mice and 189 non-transgenic littermates.</span></span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Principal
Findings</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>At the age extremes of 412 and
2224 months no differences were observed, with very low prevalence of tumors
in animals younger than 12 months, and a relatively high prevalence at age 22
months or older. However, the transgenic mice had a significant higher lung
tumor rate than their non-transgenic counterparts during the age of 1321
months, suggesting an age-related shift in lung tumor formation induced by the
lung-specific expression of the human mutant p53. Histopathology suggested a
more aggressive nature for the transgenic tumors. <span style='background:yellow'>Older
mice (&gt;13 months) had a significantly higher rate of p16 promoter
methylation (17% <i>v</i> 82%).</span> <span style='background:yellow'>In
addition, an age related effect was observed for K-Ras codons 12 or 13
mutations, but not for codon 61 mutations.</span></span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Conclusions/Significance</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>These results would suggest that
the mutant p53(273H) contributes to an acceleration in the development of
spontaneous lung tumors in these mice. <span style='background:yellow'>Combination
with other genetic and epigenetic alterations occurring after the age of 13
months is intimately linked to its oncogenic potential.</span></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif"'>Introduction</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Lung cancer is one of the most
deadly cancers worldwide <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Alberg1">[1]</a><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Takahashi1">[3]</a>,
and with more than 160,000 deaths per year. It is the number one cancer killer
in the United States (<b>SEER </b><a href="http://www.seer.cancer.gov/"
target="pmc_ext">www.seer.cancer.gov</a>; <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Ozols1">[2]</a>).
Seventy-five to eighty-five percent of lung cancers are categorized as
non-small cell cancers (NSCLC); and adenocarcinoma has become the most
prevalent NSCLC subtype <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Alberg1">[1]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Takahashi1">[3]</a>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>It has been reported that 5060%
of non-small cell lung cancers and 90% of small cell lung tumors contain p53
mutations; thus p53 alterations are among the most common genetic events in
this malignancy <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-DAmico1">[4]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Mitsudomi1">[5]</a>.
The majority of p53 mutations are missense and found within the
sequence-specific DNA-binding domain. Codon 273 is one of the most frequently
mutated sites <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-HernandezBoussard1">[6]</a><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Olivier1">[8]</a>.
The human mutant p53(273H), which has the most common substitution (arginine to
histidine), has been shown to have both dominant-negative and gain-of-function
properties <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Bargonetti1">[9]</a><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Sigal1">[13]</a>.
Unlike most tumor-derived mutant p53 proteins, p53(273H) retains partial
sequence-specific DNA-binding and transcriptional activation functions <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Chumakov1">[14]</a><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Zhang1">[17]</a>.
In addition, p53(273H) has also been reported to interact with and activate
topoisomerase I to induce genomic instability <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Sigal1">[13]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Albor1">[18]</a>
and to promote the reassociation of single-stranded RNA or DNA to a double-stranded
form <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Wu1">[19]</a>.
Thus p53(273H) could conceivably lead to increased cell proliferation, aberrant
DNA recombination, increased genomic instability and reduced chemotherapy
efficacy <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Blandino1">[20]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-ElHizawi1">[21]</a>.
p53<sup>270H/+</sup> mice (Murine p53 codon 270 correspond to human p53 codon
273) develop an increased incidence of carcinomas and B cell lymphomas compared
to p53<sup>+/&#8722;</sup> mice <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Olive1">[22]</a>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>To study the role of p53 mutation
in lung tumorigenesis, animal models in which the endogenous p53 gene is
disrupted or mutated in a lung-specific manner, or in which mutant p53
transgenes are expressed in a lung-specific manner, would be of considerable
value. It is of particular interest to generate lung cancer models which
reflect, as closely as possible, human lung cancer development. To this end, we
have developed a line of transgenic mice expressing the human p53(273H) gene
under the transcriptional control of the human surfactant protein C (SP-C)
promoter <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Duan1">[23]</a>.
Human mutant p53(273H) mRNA and protein were demonstrated specifically in lung
tissue <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Duan1">[23]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Duan2">[24]</a>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>We previously reported the
development of lung adenocarcinomas in SPCp53(273H) transgenic mice at a higher
rate compared with their littermates at the age range of 1315 months <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Duan1">[23]</a>.
Lung cancer onset data of up to 24 months has now been collected and summarized
in this report. Given their association with P53 mutations in human lung
cancer, we evaluated the rates of K-ras gene mutation and p16INK4a (p16)
promoter methylation of the lung tumors. &#947;-irradiation of tumors was
performed to evaluate the functional activity of murine p53 in these
spontaneous lung cancers.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif"'>Results</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Age influences
the rate of lung tumor formation</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Lung tumor rate and age of onset
are summarized in <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g001/"
target=figure>Figure 1</a>. Overall lung tumor rate was 23.1% (65/281) and
11.6% (22/189) in the transgenic and non-transgenic mice, respectively
(Fisher's exact test p&#8202;=&#8202;0.01). Peak differences in tumor rate
between the transgenics and non-transgenic mice occurred during the age of
1321 months (OR: 3.64 p&lt;0.01). However, no significant differences in the
rate of tumor development were observed at the extreme age ranges (412 and
2224 months).</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g001/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=100 height=86 id="Picture 7"
src="PMC2680060%20table%201_files/image001.gif" alt="Figure 1"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g001/"
target=figure>Figure 1</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Lung
tumor rate in age-matched SPC-p53(273H) transgenic mice and non-transgenic
littermates.</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Histopathologically, the tumors
in both transgenic and non-transgenic groups were well differentiated
adenocarcinoma with a predominantly bronchioloalveolar (BAC) pattern (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g002/"
target=figure>Figure 2</a>). However 13 of 24 (54%) tumors examined in
transgenic mice exhibited areas of variant histology, including areas of clear
secretory change, areas of high nuclear grade, areas of oncocytic change and areas
of solid proliferation. These variant histological patterns are evidence of
dedifferentiation, a phenomenon which human lung tumors readily exhibit. In
contrast only 1 of 11 (9%) tumors examined in the non-transgenic group showed
evidence of dedifferentiation (Fisher's exact test p&#8202;=&#8202;0.14).</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g002/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=100 height=102 id="Picture 6"
src="PMC2680060%20table%201_files/image002.gif" alt="Figure 2"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g002/"
target=figure>Figure 2</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Lung
tumors and characterization of the SPC-p53(273H) transgenic mice.</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Lung tumors
express type II pneumocyte differentiation</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Immunohistochemical analysis was
performed using antibodies against the surfactant protein C (SP-C) and the
Clara cell 10 protein (CC10), which are commonly used markers to distinguish
alveolar type II cells from Clara cells. Lung tumors collected from the
transgenic mice were all SP-C positive, suggesting that these lesions expressed
alveolar type II pneumocyte differentiation (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g003/"
target=figure>Fig 3A, 3C</a>). However, a small percentage of the lung tumor
cells also expressed CC-10 protein (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g003/"
target=figure>Fig. 3B, 3D</a>) indicating also evidence of Clara cell
differentiation. Human cancers are similarly known to express evidence of type
II pneumocyte and/or Clara cell differentiation.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g003/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=100 height=93 id="Picture 5"
src="PMC2680060%20table%201_files/image003.gif" alt="Figure 3"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g003/"
target=figure>Figure 3</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Immunohistochemical
analysis of the murine lung tumor origin.</span></b></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Incomplete cell
cycle arrest after irradiation indicates both the retention of murine wild type
p53 and reduction in p53 tumor suppression function</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>One of the most important
functions of wild type p53 is its anti-proliferation property. DNA damage
up-regulates wildtype p53 and leads to cell cycle arrest which provides
sufficient time for repair <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Harris1">[25]</a>.
Ionizing irradiation induces elevation of wild type p53 protein and results in
inhibition of cell proliferation, whereas knocking-out the p53 gene abolishes
irradiation-induced cell cycle arrest. P53 point mutation in one allele
accompanied with complete loss of the second allele of p53 is a commonly
reported phenomenon in human cancers <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Baker1">[26]</a><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Greenblatt1">[28]</a>.
However, preservation of a wild type allele has also been reported in human
neoplastic tissue <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Venkatachalam1">[29]</a><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Mazars1">[32]</a>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>To evaluate whether the murine
wild type p53 is intact in the lung cancers collected from the SPC-p53 (273H)
transgenic mice, we treated the transgenic mice using a <sup>137</sup>Cesium
&#947;-source at a dose of 5Gy/mouse. To maximize the evaluation, <i>in vivo</i>
Brdu labeling was performed. The mice were injected with Brdu at dose of 100
mg/kg 22 hr post-irradiation. Non-irradiated controls were also injected with
Brdu. Both irradiated and control mice were sacrificed and lung tissues were
harvested 2 hours after the Brdu injection. We analyzed 60 pathological images
collected from six lung tumor bearing mice three of which had been irradiated.
The rate of the BrdU positive cells was 2.61% in the non-irradiated tumors on
average, whereas the proliferating rate was 0.93% in the irradiated lung tumor
samples. Thus, compared to the non-irradiated tumors, the tumor cell
proliferation rate was reduced 2.8 fold after &#947;-irradiation treatment (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g004/"
target=figure>Fig. 4A, 4B, 4E</a>). In the normal lung tissues, Brdu positive
cell rate was 0.43% without irradiation, whereas there were almost no Brdu
positive cells (0.009%) observed in the normal lung tissues post irradiation (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g004/"
target=figure>Fig. 4C4E</a>).</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g004/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=100 height=138 id="Picture 4"
src="PMC2680060%20table%201_files/image004.gif" alt="Figure 4"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g004/"
target=figure>Figure 4</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Comparison
in the rate of cell proliferation between non-irradiated, post-irradiated lung
tumors and normal lung tissue, determined by BrdU labeling.</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>The above results suggest that
the lung tumors in the p53(273H) transgenic mice are composed of a mixed
population of cells. Some lung tumor cells retain murine wild type p53, while
others lost the functional murine p53 and continue to proliferate even after
irradiation.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>K-ras mutation
and p16INK4a (p16) methylation in the murine lung tumors</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>The long latency period for tumor
development in the transgenic mice suggests collaboration with other oncogenic
events for lung cancer development. Given the high prevalence of K-ras and p16
gene deficiencies in human lung cancers <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Rodenhuis1">[33]</a><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Belinsky1">[36]</a>,
we evaluated for K-ras gene mutations and p16 promoter methylation in the
spontaneous lung cancers in both transgenic and non-transgenic animals.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'>We analyzed 28
murine lung tumors, 21 from the transgenic mice and 7 tumors from
non-transgenic mice.</span><span lang=EN style='font-size:12.0pt;font-family:
"Times New Roman","serif"'> <span style='background:yellow'>Six of the
transgenic mice were 412 months, and fifteen 1324 months.</span> <span
style='background:yellow'>All non-transgenic tumors were collected at the age
of 1324 months, given their rare occurrence at an earlier age.</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'>It has been
reported that K-ras mutations occur mainly in codons 12, 13 and 61 in murine
lung tumors <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Wang1">[37]</a>,
thus we investigated the DNA sequences of exons 2 and 3 that contain codons 12,
13 and 61 using PCR amplification followed by DNA sequencing.</span><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'> <span
style='background:yellow'>Among 21 transgenic tumors, ten tumor samples (47.6%)
contained K-ras mutations.</span> <span style='background:yellow'>These
included four in exon 2 (codons 12 or 13) and six in exon 3 (codon 61).</span> <span
style='background:yellow'>Among 7 non-transgenic tumors, two mutations were
found in exon 2 (codon 12) and two in codon 61 (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/table/pone-0005563-t001/"
target=true>Table 1</a>).</span> In all cases, each tumor contained a single
site mutation at the second position of the codon.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/table/pone-0005563-t001/"
target=table><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=204 height=142 id="Picture 3"
src="PMC2680060%20table%201_files/image005.png" alt="Table 1"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/table/pone-0005563-t001/"
target=table>Table 1</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'> <span style='background:yellow'>K-ras
mutations and p16INK4a promoter methylation in spontaneous lung neoplasm from
SPC-p53(273H) transgenic mice and Non-Transgenic controls.</span></span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'>Age differences
in the type of K-ras mutations were observed, with a preference for codons
1213 mutations to occur in the 1324 month group (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g005/"
target=figure>Fig. 5A</a>) with a peak at 1618 months (3/6 in transgenics and
5/9 in transgenic and non-transgenic tumors).</span><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'> <span
style='background:yellow'>In mice younger than 15 months no mutations at codons
1213 of K-ras were found (0/10 tumors).</span> <span style='background:yellow'>The
rate of tumors with codon 1213 mutations was higher in the 1618 month cohort
compared to the younger age cohort in the transgenic mice (3/6 vs. 0/10,
Fisher's exact test p&#8202;=&#8202;0.18).</span> <span style='background:yellow'>Altogether
(including non-transgenics) the 1618 month cohort had a higher rate of
mutations at codons 1213 of K-ras compared to the younger age cohort (5/9 vs.
0/10).</span> <span style='background:yellow'>A similar rate of K-ras mutations
were observed between transgenic and non-transgenic animals (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g005/"
target=figure>Fig. 5B</a>).</span></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g005/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=100 height=123 id="Picture 2"
src="PMC2680060%20table%201_files/image006.gif" alt="Figure 5"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g005/"
target=figure>Figure 5</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>K-ras
mutations in lung tumors of transgenic and non-transgenic control mice.</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Among four mutations in codon 12,
three were G to A transitions, GGT to GAT; and one was G to T transversion, GGT
to GTT (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g005/"
target=figure>Fig. 5C</a>). Two mutations were found in codon 13; both were G
to A transitions, GGC to GAC (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g005/"
target=figure>Fig. 5D</a>). Among eight mutations in codon 61, six mutations
were A to G transitions (CAA to CGA) and two were A to T transversions, CAA to
CTA (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g005/"
target=figure>Fig. 5E</a>).</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'>P16 promoter
methylation (methylation specific PCR) was detected in 19 of 28 (68%) lung
tumors (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g006/"
target=figure>Fig. 6</a>).</span><span lang=EN style='font-size:12.0pt;
font-family:"Times New Roman","serif"'> <span style='background:yellow'>Overall
13 of 21 (62%) transgenic lung tumors and 6 of 7 (86%) non-transgenic lung
tumors contained p16 promoter methylation.</span> <span style='background:yellow'>Only
one of six (17%) tumors tested at the age cohorts of 412 months contained p16
promoter methylation.</span> <span style='background:yellow'>In contrast, among
the 15 transgenic tumors collected from the 1324 month cohorts, 12 (80%) were
found to have p16 promoter methylation (Fisher's exact test, p&lt;0.1).</span> <span
style='background:yellow'>Altogether, 18 of 22 (82%) tumors from 1324 months
(including non-transgenics) had p16 promoter methylation, which is
statistically higher (Fisher's exact test, p&lt;0.1) than for the 412 month
group.</span> <span style='background:yellow'>A similar promoter methylation rate in the tumors of the
transgenics and non-transgenic controls was found (<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/table/pone-0005563-t001/"
target=true>Table 1</a>).</span></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g006/"
target=figure><span style='font-size:12.0pt;font-family:"Times New Roman","serif";
text-decoration:none'><img border=0 width=100 height=68 id="Picture 1"
src="PMC2680060%20table%201_files/image007.gif" alt="Figure 6"></span></a></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/figure/pone-0005563-g006/"
target=figure>Figure 6</a></span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>p16INK4a
promoter methylations in lung tumors of transgenic and non-transgenic control
mice.</span></b></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif"'>Discussion</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>The most important function of
wild type p53 is the sequence specific transactivation of target genes. In
normal cells, the steady state level of p53 protein is low and the half-life of
p53 is very short due to the presence of negative regulators, such as Mdm2, JNK
and Pirh2 <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Chen1">[38]</a><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Picksley1">[44]</a>.
However, DNA damage (e.g., radiation) induces a prominent increase in p53
protein levels <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Brugarolas1">[45]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Xiong1">[46]</a>.
The increase in wild type p53 protein in response to DNA damage is believed to
regulate p21 to prevent cells with genetic lesions to proliferate <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-ElDeiry1">[47]</a>.
Either cell cycle arrest or apoptotic cell death to remove the damaged cell
permanently follows <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Ko1">[48]</a>.
Mutations of p53, the vast majority within the sequence-specific DNA-binding
domain of the protein, produce mutant proteins unable to bind to and
transactivate the target genes that mediate tumor suppression <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Ko1">[48]</a><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-vanOijen1">[50]</a>.
Restoration of p53 function leads to tumor regression in vivo <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Ventura1">[51]</a>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>The general assumption is that
tumor cells with intact p53 will stop proliferating after irradiation, whereas
tumor cells with deficient p53 will proliferate continually post irradiation.
Our results demonstrated that some tumor cells in the transgenic animals failed
to initiate cell cycle arrest post irradiation, so that 0.93% lung tumor cells
were Brdu positive. In comparison, there were no Brdu positive cells observed
in the normal lung tissues collected from the same mouse post irradiation.
Given that even one copy of intact p53 could cause a complete cell cycle arrest
in mice lungs post irradiation, it follows that the Brdu positive cells
observed in the lung tumors have lost p53 function completely.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Several potential mechanisms for
p53 mutant induced tumorigenesis have been proposed. One possibility is that
mutant p53 inhibits the sequence-specific DNA-binding and transactivation
functions of wild-type p53 in a dominant-negative manner by forming
hetero-oligomeric complexes with it <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Farmer1">[10]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Kern1">[11]</a>.
Alternatively, certain p53 mutants may possess intrinsic oncogenic potential,
as their introduction into cells lacking endogenous p53 has been shown to
enhance the tumorigenicity of these cells <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Dittmer1">[12]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-vanOijen1">[50]</a>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Since human and murine p53
proteins are fully capable of forming hetero-oligomeric complexes <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Milner1">[52]</a>,
it is therefore possible that human p53(273H) affected murine wild type p53
function in the transgenic mice studied through a dominant-negative effect
leading to increased cell proliferation <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Wijnhoven1">[53]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Duan3">[54]</a>.
Interestingly, the tumor rate differences observed between the transgenics and
the non-transgenic counterparts beginning at 13 months equalizes after 22
months, suggesting that the genome instability associated with senescence <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Lombard1">[55]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Busuttil1">[56]</a>
is diluting any difference that the transgene effect could produce.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Previously we reported that the
level of the mouse wild-type p53 protein was reduced in 10 of 10 tumor samples
as compared to matched normal lung tissue of the transgenic mouse <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Duan4">[57]</a>.
The reduction in the level of murine wildtype p53 protein may be associated
with overexpression of p53 ubiquitinprotein ligase Pirh2 and the
dominant-negative effect of the mutant p53.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>One copy of the wild type p53 is
sufficient to cause cell cycle arrest post irradiation <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Duan3">[54]</a>,
which may explain the delay in tumor development in our transgenic animals with
the two murine wildtype p53 alleles in addition to the human mutant. This would
also suggests that the p53(273H) has a weak dominant-negative effect. Previous
in vitro studies support this notion <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Chumakov1">[14]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Zhang1">[17]</a>.
At the age of 1321 months, when additional genetic and epigenetic alterations
are able to combine with the mutant p53, a significant difference in tumor
formation between the transgenic and the non-transgenic mice would then be
appreciated.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'>We analyzed 28
spontaneous lung tumors and found that 27% of lung tumors had K-ras mutations
(all somatic) at codons 1213 at the age of 1324 months, whereas, no mutation
was detected at these codons at an earlier age.</span><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'> <span
style='background:yellow'>Thus the onset of K-ras mutations in codons 12 and 13
in murine lung tumor appear to be an age related phenomenon, appearing at a
similar rate in tumor-developing transgenic and non-transgenic littermates.</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Murine lung tumors have been
shown to contain a high frequency of K-ras mutation in codon 61 <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Wang1">[37]</a>.
This type of Kras mutation is extremely rare in human tumors, especially lung
cancer. <span style='background:yellow'>Among 28 lung tumors, eight tumors
(29%) contained K-ras mutation in codon 61, and its frequency was similar
between transgenics (27%) and non-transgenics (29%) and between the 412 months
transgenic cohort (33%) and the 1324 months transgenic cohort (27%),
suggesting its lack of association with age or collaboration with P53 mutations
(415 months vs. 1624 months: Fisher's exact p&#8202;=&#8202;0.936).</span></span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>P16 gene promoter
hypermethylation is a common event in lung cancers <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Belinsky1">[36]</a>;
up to 80% in lung adenocarcinomas <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Liu1">[58]</a>.
<span style='background:yellow'>Our study demonstrated aberrant methylation of
the p16 gene more frequently in the 1324 months cohort than in the 412 months
cohort (82% vs. 17% respectively).</span> These results would suggest that
inactivation of p16 by methylation of its promoter region is, similar to K-ras
codons 1213 mutations, a late age dependent event contributing to lung tumor
formation in the p53(273H) transgenic mice.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>In summary, expression of mutant
p53 (273H) in mice lungs resulted in an age-related demographic shift in lung
tumor formation in the transgenic mice. <span style='background:yellow'>The
latency period for tumors to develop in these transgenic mice would also
suggest that mutant p53(273H) combine with other age-related genetic or
epigenetic alterations, such as mutation at codon 12 or 13 of K-ras gene and
inactivation of p16 by methylation of its promoter region, to promote lung
tumor formation and progression in the p53(273H) transgenics.</span> Our model
may recapitulate what occurs in human cancer, where age specific differences
have been reported <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Atwal1">[59]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Anders1">[60]</a>,
and where tumor formation substantially lags behind the oncogenic stimulus <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-LeCalvez1">[61]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Landi1">[62]</a>.
While p53 and K-ras codons 12/13 mutations and p16 promoter methylation status
are well described in human lung cancers, the influence of age in the
likelihood of these abnormalities to combine with early genetic events has not
been previously explored. Our study supports the multi-step genetic hits
process documented in other malignancies for which familial cancer clusters are
available, and suggests the need to evaluate age related differences in the
pattern of genetic and epigenetic aberrations linked to lung cancer in patient
with this disease. Relevance to treatment efficacy with conventional
chemotherapy or molecularly targeted treatment may be demonstrated by such studies.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif"'>Materials
and Methods</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>SPC-p53(273H)
transgenic and p53 knockout mice</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'>The
SPC-p53(273H) transgenic mice were generated by microinjection of a 6.7-kb
fragment of the SPC-p53(273H) construct into the pro-nuclei of FVB/N mouse
zygotes as previously reported <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Duan1">[23]</a>.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>All lung samples were carefully
examined with the use of a dissecting microscope. All tumors observed were
processed for histological analysis. In addition, 30% of lung samples with no
visible surface tumors were subjected to random histological analysis. All
protocols on animal subjects were approved by The Ohio State University
Institutional Laboratory Animal Care and Use Committee.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Irradiation</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Total body irradiation was
performed using a <sup>137</sup>Cesium &#947;-source at a dose of 5Gy/mouse. At
24 h (hours) after irradiation, mice were sacrificed and lung tumors and normal
lung tissues were harvested.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Brdu uptake and
cell proliferation indexes</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Mice were injected
(intraperitoneally) with Bromodeoxyuridine (BrdU) 100 mg/kg in 0.9% NaCl. Lung
tumor and normal tissue were harvested 2 h after the injection, and then the
tissues were fixed in 10% neutral buffered formalin for 12 h. Paraffin embedded
tissue was cut and incubated with monoclonal anti-Brdu antibody (DAKO
Corporation, Carpinteria, CA) for Immunohistochemical analysis. The number of
Brdu positive cell on a slide was counted directly under a compound microscope
(400 magnification). The average percentage of BrdU positive cells was obtained
from thirty random images (three mice per group).</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Methylation
Specific PCR (MS-PCR)</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>One microgram of genomic DNA was
denatured by NaOH (final concentration, 0.275 M) for 10 min at 37C. The
denatured DNA was then treated with 10 l of 10 mM hydroquinone, 520 l of 3 M
sodium bisulfite at 50C overnight. The bisulfite-treated DNA was purified with
Qiaquick gel extraction kit (Qiagen, Germany) according to the manufacturer's
instruction. The DNA was then precipitated with sodium acetate (final
concentration, 0.45 M) and isopropanol. DNA was eluted with dH<sub>2</sub>O and
used for PCR. The primers used for the MS-PCR were (U3&#8202;=&#8202;<i>GTGATTGGGTGGGTATTGAATTTT
TGTG</i>, U4&#8202;=&#8202;<i>CACACATCATACACACAA CCCTAAACCA</i>) for
unmethylated, (M3&#8202;=&#8202;<i>CGATTGGGCGGGTATTGAATTTTCGC</i>,
M4&#8202;=&#8202;<i>CACGTCATACACACGACCCTA AACCG</i>) for methylated, and
(W1&#8202;=&#8202;<i>ACTGAATC TCCGCGAGGAAAGCG</i>, W2&#8202;=&#8202;<i>GCACACGGCCCTGGGCCGCCG</i>)
for unmodified sequences flanking the p16 translation start site <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Sharpless1">[63]</a>.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>DNA Sequencing</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>K-ras mutations were identified
by utilizing the polymerase chain reaction (PCR) technique to amplify the
second and third exons (GenBank accession NC_00072, the start codon of K-ras is
located in the second exon) followed by sequence analysis of the amplified
product. Primers used to amplify exon 2 were <i>5&#8242;- AGGCCTGCTGAAAATGACTGA</i>
(forward), <i>5&#8242;- TTCTTGCACCTATGGTTCCCTA</i> (reverse). Primers used to
amplify exon 3 were <i>5&#8242;-GGCCAGGAGTGCATTAAGAC</i> (forward), <i>5&#8242;-
TGCAGGCATAACA ATTAGCAA</i> (reverse). The primers were also used for sequencing
analysis.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Histology and
Immunohistochemistry</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Immediately following tissue
harvesting, lung tumors and normal lung tissues were placed in 10% neutral
buffered formalin for 12 h, rinsed with water, and preserved in 1
Phosphate-buffered Saline (PBS). Paraffin embedded tissue was cut at 4 microns,
placed on slides and stained with hematoxylin and eosin (HE). Additional
sections for immunohistochemistry (IHC) were placed in a 60C oven for 1 h,
cooled, deparaffinized and rehydrated through xylene and graded ethanol
solutions to water in standard fashion. All slides were quenched for 5 minutes
in a 3% hydrogen peroxide solution in methanol to block endogenous peroxidase.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>Antigen retrieval was performed
by placing the tissue sections in a citric acid solution (Dako's Target
Retrieval Solution, pH 6.1) for 30 minutes at 94C using a vegetable steamer.
Slides were then placed on a Dako Autostainer immunostaining system for IHC.
Slides were blocked with 10% normal goat serum for 1 h before application of
primary antibody. The detection system used was a labeled Streptavidin-Biotin
Complex. Slides were then counterstained in hematoxylin, dehydrated through
graded ethanol solutions and cover slipped.</span></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>The antibodies used were:
anti-human p53 specific monoclonal antibody (BD PharMingen, San Diego, CA);
anti-&#946;-Actin monoclonal (Sigma, St. Louis, Missouri); anti-SP-C polyclonal
(Santa Cruz, Santa Cruz, CA); anti-CC10 polyclonal (Santa Cruz, Santa Cruz, CA)
and anti-Brdu monoclonal (DAKO Corporation, Carpinteria, CA).</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:13.5pt;font-family:"Times New Roman","serif"'>Statistical
Methods</span></b></p>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif";background:yellow'>Given the
limited number of lung tumors in certain age cohorts, age cohorts were combined
into three groups, 412, 1321 and 2224 months for comparisons between
transgenic and non-transgenic mice. In order to investigate how the proportion
of lung tumors vary between transgenic and non-transgenic mice over age cohorts
logistic regression models were used <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Hosmer1">[64]</a>.</span><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'> <span
style='background:yellow'>Using this model, differences between types of mice
for each age cohort group were tested and odds ratios (OR) estimated through
the interaction of mouse type and age cohort group.</span> <span
style='background:yellow'>The overall comparison of tumor rates and mouse type
were compared by Fisher's exact test.</span> Multiple measurements for the % of
cells BrdU positive were averaged for each mouse. Summary statistics were
computed on the average of measurements. <span style='background:yellow'>Age
cohorts for K-ras mutation or p16 methylation were grouped and compared via
Fisher's exact test due to the limited number of tumors.</span> P-values were
adjusted for multiple comparisons by the Holm procedure <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Holm1">[65]</a>,
<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-Sankoh1">[66]</a>.
Briefly the Holm procedure is a modified Bonferroni type procedure which
maintains the experiment-wise error rate. Adjusted p-values were considered
significant at the 0.10 level given the exploratory nature of these studies and
all tests were two sided. All analyses were performed using STATA statistical
software, version 10.0 <a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#pone.0005563-StataCorp1">[67]</a>.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif"'>Acknowledgments</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><span lang=EN style='font-size:
12.0pt;font-family:"Times New Roman","serif"'>We thank the Transgenic Core
Facility, Pathology Core Facility of The Ohio State University (OSU).</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif"'>Footnotes</span></b></p>

</div>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Competing
Interests: </span></b><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>The
authors have declared that no competing interests exist.</span></p>

<p class=MsoNormal style='line-height:normal'><b><span lang=EN
style='font-size:12.0pt;font-family:"Times New Roman","serif"'>Funding: </span></b><span
lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>The work
was supported by NCI grant CA76970 to M. V., American Cancer Society
Institutional Seed Grant IRG-67-003-44 to W. D. and NCI grant P30 CA16058 to
the Ohio State University Comprehensive Cancer Center. The funders had no role
in study design, data collection and analysis, decision to publish, or
preparation of the manuscript.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'><a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/"
title="Go to other sections in this page">Go to:</a></span></p>

<div style='border:none;border-bottom:solid #97B0C8 1.0pt;padding:0in 0in 0in 0in'>

<p class=MsoNormal style='line-height:normal;border:none;padding:0in'><b><span
lang=EN style='font-size:18.0pt;font-family:"Times New Roman","serif"'>References</span></b></p>

</div>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>1.
Alberg AJ, Brock MV, Samet JM. Epidemiology of lung cancer: Looking to the
future. J Clin Oncol. 2005;23:31753185. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/15886304" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>2.
Ozols RF, Herbst RS, Colson YL, Gralow J, Bonner J, et al. American Society of
Clinical Oncology. Clinical cancer advances 2006: major research advances in
cancer treatment, prevention, and screeninga report from the American Society
of Clinical Oncology. J Clin Oncol. 2007;25:146162. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/17158528" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>3.
Takahashi T. Lung cancer: an ever increasing store of in-depth basic knowledge
and the beginning of its clinical application. Oncogene. 2002;21:68686869. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/12362268" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>4.
D'Amico D, Carbone D, Mitsudomi T, Nau M, Fedorko J, et al. High frequency of
somatically acquired p53 mutations in small-cell lung cancer cell lines and tumors.
Oncogene. 1992;7:339346. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/1312696"
target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>5.
Mitsudomi T, Steinberg SM, Nau MM, Carbone D, D'Amico D, et al. p53 gene
mutations in non-small-cell lung cancer cell lines and their correlation with
the presence of ras mutations and clinical features. Oncogene. 1992;7:171180.
[<a href="http://www.ncbi.nlm.nih.gov/pubmed/1311061" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>6.
Hernandez-Boussard TM, Hainaut P. A specific spectrum of <i>p53</i> mutations
in lung cancer from smokers: review of mutations compiled in the IARC <i>p53</i>
database. Environ Health Perspect. 1998;106:385391. [<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1533115/">PMC free article</a>]
[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9637795" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>7.
Hernandez-Boussard T, Rodriguez-Tome P, Montesano R, Hainaut P. IARC <i>p53</i>
mutation database: a relational database to compile and analyze <i>p53</i>
mutations in human tumors and cell lines. Hum Mutat. 1999;14:18. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/10447253" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>8.
Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, et al. The IARC TP53
Database: new online mutation analysis and recommendations to users. Hum Mutat.
2002;19:607614. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/12007217"
target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>9.
Bargonetti J, Reynisdottir I, Friedman PN, Prives C. Site-specific binding of
wild-type <i>p53</i> to cellular DNA is inhibited by SV40 T antigen and mutant <i>p53</i>.
Genes Dev. 1992;6:18861898. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/1398068" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>10.
Farmer GE, Bargonetti J, Zhu H, Friedman P, Prywes R, et al. Wild-type <i>p53</i>
activates transcription in vitro. Nature. 1992;358:8386. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/1614538" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>11.
Kern SE, Pietelpol JA, Thiagalingam S, Seymour A, Kinzler KW, et al. Oncogenic
forms of <i>p53</i> inhibit <i>p53</i>-regulated gene expression. Science.
1992;256:827830. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/1589764"
target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>12.
Dittmer D, Pati S, Zambetti G, Chu S, Teresky AK. Gain of function mutations in
<i>p53</i>. Nat Genet. 1993;4:4246. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/8099841" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>13.
Sigal A, Rotter V. Oncogenic mutations of the p53 tumor suppressor: the demons
of the guardian of the genome. Cancer Res. 2000;60:67886793. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/11156366" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>14.
Chumakov AM, Miller CW, Chen DL, Koeffler HP. Analysis of <i>p53</i>
transactivation through high-affinity binding sites. Oncogene.
1993;8:30053011. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/8414502"
target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>15.
Kawamura M, Yamashita T, Segawa K, Kaneuchi M, Shindoh M, et al. The 273rd
codon mutants of <i>p53</i> show growth modulation activities not correlated
with <i>p53</i>-specific transactivation activity. Oncogene. 1996;12:23612367.
[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8649776" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>16.
Park DJ, Nakamura H, Chumakov AM, Said JW, Miller CW, et al. Transactivational
and DNA binding abilities of endogenous <i>p53</i> in <i>p53</i> mutant cell
lines. Oncogene. 1994;9:18991906. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/8208536" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>17.
Zhang W, Funk WD, Wright WE, Shay JW, Deisseroth AB. Novel DNA binding of <i>p53</i>
mutants and their role in transcriptional activation. Oncogene.
1993;8:25552559. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/8361764"
target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>18.
Albor A, Kaku S, Kulesz-Martin M. Wild-type and mutant forms of p53 activate
human topoisomerase I: a possible mechanism for gain of function in mutants.
Cancer Res. 1998;58:20912094. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/9605749" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>19.
Wu L, Bayle JH, Elenbaas B, Pavletich NP, Levine AJ. Alternatively spliced
forms in the carboxy-terminal domain of the p53 protein regulate its ability to
promote annealing of complementary single strands of nucleic acids. Mol Cell
Biol. 1995;15:497504. [<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC231999/">PMC free article</a>]
[<a href="http://www.ncbi.nlm.nih.gov/pubmed/7528329" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>20.
Blandino G, Levine AJ, Oren M. Mutant p53 gain of function: differential
effects of different p53 mutants on resistance of cultured cells to
chemotherapy. Oncogene. 1999;18:477485. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/9927204" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>21.
El-Hizawi S, Lagowski JP, Kulesz-Martin M, Albor A. Induction of gene
amplification as a gain-of-function phenotype of mutant p53 proteins. Cancer
Res. 2002;62:32643270. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/12036943"
target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>22.
Olive KP, Tuveson DA, Ruhe ZC, Yin B, Willis NA, et al. Mutant p53 gain of
function in two mouse models of Li-Fraumeni syndrome. Cell. 2004;119:847860. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/15607980" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>23.
Duan W, Ding H, Subler MA, Zhu WG, Zhang H, et al. Lung-specific expression of
human mutant p53-273H is associated with a high frequency of lung
adenocarcinoma in transgenic mice. Oncogene. 2002a;21:78317838. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/12420220" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>24.
Duan W, Ding H, Zhu WG, Srinivasan K, Otterson GA, et al. RT-PCR heteroduplex
analysis permits differentiation of transgene and host gene expression in a
transgenic animal model. Biotechniques. 2002b;33:5866. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/12139258" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>25.
Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops.
Oncogene. 2005;24:28992908. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/15838523" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>26.
Baker SJ, Fearon ER, Nigro JM, Hamilton SR, Preisinger AC, et al. Chromosome 17
deletions and p53 gene mutations in colorectal carcinomas. Science.
1989;244:217221. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/2649981"
target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>27.
Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter R, et al. Mutations in
the p53 gene occur in diverse human tumour types. Nature. 1989;342:705708. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/2531845" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>28.
Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor
suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer
Res. 1994;54:48554878. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/8069852"
target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>29.
Venkatachalam S, Shi YP, Jones SN, Vogel H, Bradley A, et al. Retention of
wild-type p53 in tumors from p53 heterozygous mice: reduction of p53 dosage can
promote cancer formation. EMBO J. 1998;17:46574667. [<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1170795/">PMC free article</a>]
[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9707425" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>30.
Mulligan LM, Matlashewski GJ, Scrable HJ, Cavenee WK. Mechanisms of p53 loss in
human sarcomas. Proc Natl Acad Sci U S A. 1990;87:58635867. [<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC54429/">PMC free article</a>]
[<a href="http://www.ncbi.nlm.nih.gov/pubmed/2143022" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>31.
Davidoff AM, Humphrey PA, Iglehart JD, Marks JR. Genetic basis for p53
overexpression in human breast cancer. Proc Natl Acad Sci U S A.
1991;88:50065010. [<a href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC51796/">PMC
free article</a>] [<a href="http://www.ncbi.nlm.nih.gov/pubmed/2052583"
target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>32.
Mazars R, Spinardi L, BenCheikh M, Simony-Lafontaine J, Jeanteur P, et al. p53
mutations occur in aggressive breast cancer. Cancer Res. 1992;52:39183923. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/1617667" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>33.
Rodenhuis S, Slebos RJ, Boot AJ, Evers SG, Mooi WJ, et al. Incidence and
possible clinical significance of K-ras oncogene activation in adenocarcinoma
of the human lung. Cancer Res. 1988;48:57385741. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/3048648" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>34.
You M, Candrian U, Maronpot RR, Stoner GD, Anderson MW. Activation of the
Ki-ras protooncogene in spontaneously occurring and chemically induced lung
tumors of the strain A mouse. Proc Natl Acad Sci U S A. 1989;86:30703074. [<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC287066/">PMC free article</a>]
[<a href="http://www.ncbi.nlm.nih.gov/pubmed/2654935" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>35.
Otterson GA, Khleif SN, Chen W, Coxon AB, Kaye FJ. CDKN2 gene silencing in lung
cancer by DNA hypermethylation and kinetics of p16INK4 protein induction by
5-aza 2'deoxycytidine. Oncogene. 1995;11:12111216. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/7566983" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>36.
Belinsky SA, Nikula KJ, Palmisano WA, Michels R, Saccomanno G, et al. Aberrant
methylation of p16(INK4a) is an early event in lung cancer and a potential
biomarker for early diagnosis. Proc Natl Acad Sci U S A. 1998;95:1189111896. [<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC21736/">PMC free article</a>]
[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9751761" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>37.
Wang Y, Zhang Z, Lubet R, You M. Tobacco smoke-induced lung tumorigenesis in
mutant A/J mice with alterations in K-ras, p53, or Ink4a/Arf. Oncogene.
2005;24:30423049. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/15846305"
target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>38.
Chen J, Wu X, Lin J, Levine AJ. mdm-2 inhibits the G1 arrest and apoptosis
functions of the p53 tumor suppressor protein. Mol Cell Biol.
1996;16:24452452. [<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC231233/">PMC free article</a>]
[<a href="http://www.ncbi.nlm.nih.gov/pubmed/8628312" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>39.
Fuchs SY, Adler V, Buschmann T, Yin Z, Wu X, et al. JNK targets p53
ubiquitination and degradation in nonstressed cells. Genes Dev.
1998;12:26582663. [<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC317120/">PMC free article</a>]
[<a href="http://www.ncbi.nlm.nih.gov/pubmed/9732264" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>40.
Haupt Y, Maya R, Kazaz A, Oren M. Mdm2 promotes the rapid degradation of p53.
Nature. 1997;387:296299. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/9153395"
target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>41.
Kubbutat MH, Jones SN, Vousden KH. Regulation of p53 stability by Mdm2. Nature.
1997;387:299303. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/9153396"
target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>42.
Leng RP, Lin Y, Ma W, Wu H, Lemmers B, et al. Pirh2, a p53-induced
ubiquitin-protein ligase, promotes p53 degradation. Cell. 2003;112:779791. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/12654245" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>43.
Momand J, Zambetti GP, Olson DC, George D, Levine AJ. The mdm-2 oncogene
product forms a complex with the p53 protein and inhibits p53-mediated
transactivation. Cell. 1992;69:12371245. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/1535557" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>44.
Picksley SM, Lane DP. The p53-mdm2 autoregulatory feedback loop: a paradigm for
the regulation of growth control by p53? Bioessays. 1993;15:689690. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/7506024" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>45.
Brugarolas J, Chandrasekaran C, Gordon JI, Beach D, Jacks T, et al. Radiation-induced
cell cycle arrest compromised by p21 deficiency. Nature. 1995;377:552557. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/7566157" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>46.
Xiong Y, Hannon GJ, Zhang H, Casso D, Kobayashi R, et al. p21 is a universal
inhibitor of cyclin kinases. Nature. 1993;366:701704. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/8259214" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>47.
El-Deiry WS, Tokino T, Velculescu VE, Levy DB, Parsons R, et al. WAF1, a
potential mediator of p53 tumor suppression. Cell. 1993;75:817825. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/8242752" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>48.
Ko LJ, Prives C. p53: puzzle and paradigm. Genes Dev. 1996;10:10541072. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/8654922" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>49.
Cho Y, Gorina S, Jeffrey PD, Pavletich NP. Crystal structure of a p53 tumor
suppressor-DNA complex: understanding tumorigenic mutations. Science.
1994;265:346355. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/8023157"
target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>50.
van Oijen MG, Slootweg PJ. Gain-of-function mutations in the tumor suppressor
gene p53. Clin Cancer Res. 2000;6:21382145. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/10873062" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>51.
Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, et al. Restoration of
p53 function leads to tumour regression in vivo. Nature. 2007;445:661665. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/17251932" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>52.
Milner J, Medcalf EA, Cook AC. Tumor suppressor p53: analysis of wild-type and
mutant p53 complexes. Mol Cell Biol. 1991;11:1219. [<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC359578/">PMC free article</a>]
[<a href="http://www.ncbi.nlm.nih.gov/pubmed/1986215" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>53.
Wijnhoven SW, Speksnijder EN, Liu X, Zwart E, vanOostrom CT, et al.
Dominant-negative but not gain-of-function effects of a p53. R270H mutation in
mouse epithelium tissue after DNA damage. Cancer Res. 2007;67:46484656. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/17510390" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>54.
Duan W, Gao L, Jin D, Otterson GA, Villalona-Calero MA. Lung specific
expression of a human mutant p53 affects cell proliferation in transgenic mice.
Transgenic Res. 2008;17:355366. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/17968669" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>55.
Lombard DB, Chua KF, Mostoslavsky R, Franco S, Gostissa M, et al. DNA repair,
genome stability, and aging. Cell. 2005;120:497512. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/15734682" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>56.
Busuttil R, Bahar R, Vijg J. Genome dynamics and transcriptional deregulation
in aging. Neuroscience. 2007;145:13411347. [<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC1905494/">PMC free article</a>]
[<a href="http://www.ncbi.nlm.nih.gov/pubmed/17137723" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>57.
Duan W, Gao L, Druhan LJ, Zhu WG, Morrison C, et al. Expression of Pirh2, a
newly identified ubiquitin protein ligase, in lung cancer. J Natl Cancer Inst.
2004;96:17181721. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/15547185"
target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>58.
Liu Y, An Q, Li L, Zhang D, Huang J, et al. Hypermethylation of p16INK4a in
Chinese lung cancer patients: biological and clinical implications.
Carcinogenesis. 2003;24:18971901. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/12970072" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>59.
Atwal GS, Rabadn R, Lozano G, Strong LC, Ruijs MWG, et al. An
Information-Theoretic Analysis of Genetics, Gender and Age in Cancer Patients.
PLoS ONE. 2008;3(4):e1951. [<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2276689/">PMC free article</a>]
[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18398474" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>60.
Anders CK, Acharya CR, Hsu DS, Broadwater G, Garman K, et al. Age-Specific
Differences in Oncogenic Pathway Deregulation Seen in Human Breast Tumors. PLoS
ONE. 2008;3(1):e1373. [<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2148101/">PMC free article</a>]
[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18167534" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>61.
Le Calvez F, Mukeria A, Hunt JD, Kelm O, Hung RJ, Tanire P, et al. TP53 and
KRAS mutation load and types in lung cancers in relation to tobacco smoke:
distinct patterns in never, former, and current smokers. Cancer Res.
2005;65:50765083. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/15958551"
target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>62.
Landi MT, Dracheva T, Rotunno M, Figueroa JD, Liu H, et al. Gene expression
signature of cigarette smoking and its role in lung adenocarcinoma development
and survival. PLoS ONE. 2008;3:e1651. [<a
href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2249927/">PMC free article</a>]
[<a href="http://www.ncbi.nlm.nih.gov/pubmed/18297132" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>63.
Sharpless NE, Bardeesy N, Lee KH, Carrasco D, Castrillon DH, et al. Loss of
p16Ink4a with retention of p19Arf predisposes mice to tumorigenesis. Nature.
2001;413:8691. [<a href="http://www.ncbi.nlm.nih.gov/pubmed/11544531"
target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>64.
Hosmer DW, Lemeshow S. Applied Logistic Regression, Second Edition. John Wiley
&amp; Sons; 2000. </span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>65.
Holm S. A simple sequentially rejective multiple test procedure. Scandinavian
Journal of Statistics. 1979;6:6570.</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>66.
Sankoh AJ, Huque MF, Dubey SD. Some comments on frequently used multiple
endpoint adjustment methods in clinical trials. Stat Med. 1979;16:25292542. [<a
href="http://www.ncbi.nlm.nih.gov/pubmed/9403954" target="pmc_ext">PubMed</a>]</span></p>

<p class=MsoNormal style='margin-bottom:0in;margin-bottom:.0001pt;line-height:
normal'><span lang=EN style='font-size:12.0pt;font-family:"Times New Roman","serif"'>67.
StataCorp . Stata Statistical Software: Release 10. College Station, TX: 2007. </span></p>

<ul type=disc>
 <li class=MsoNormal style='line-height:normal;display:none'><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif";display:
     none'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#__abstractid1124719title">Abstract</a></span></li>
 <li class=MsoNormal style='line-height:normal;display:none'><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif";display:
     none'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#s1title">Introduction</a></span></li>
 <li class=MsoNormal style='line-height:normal;display:none'><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif";display:
     none'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#s2title">Results</a></span></li>
 <li class=MsoNormal style='line-height:normal;display:none'><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif";display:
     none'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#s3title">Discussion</a></span></li>
 <li class=MsoNormal style='line-height:normal;display:none'><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif";display:
     none'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#s4title">Materials
     and Methods</a></span></li>
 <li class=MsoNormal style='line-height:normal;display:none'><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif";display:
     none'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#__ackid1028574title">Acknowledgments</a></span></li>
 <li class=MsoNormal style='line-height:normal;display:none'><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif";display:
     none'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#__fn-groupid1041425title">Footnotes</a></span></li>
 <li class=MsoNormal style='line-height:normal;display:none'><span lang=EN
     style='font-size:12.0pt;font-family:"Times New Roman","serif";display:
     none'><a
     href="http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2680060/#__ref-listid1028581title">References</a></span></li>
</ul>

<div class=MsoNormal align=center style='margin-bottom:0in;margin-bottom:.0001pt;
text-align:center;line-height:normal'><span lang=EN style='font-size:12.0pt;
font-family:"Times New Roman","serif"'>

<hr size=2 width="100%" align=center>

</span></div>

<p class=MsoNormal align=center style='margin-bottom:0in;margin-bottom:.0001pt;
text-align:center;line-height:normal'><span lang=EN style='font-size:12.0pt;
font-family:"Arial","sans-serif"'>Articles from PLoS ONE are provided here
courtesy of <b>Public Library of Science</b></span></p>

<p class=MsoNormal>&nbsp;</p>

</div>

</body>

</html>
